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CHAPTER 1. GENERAL INTRODUCTION 
INTRODUCTION 
Monoclonal antibodies are widely used as therapeutic and diagnostic agents and 
allow for the detection and quantification of many biological compounds. B cell 
hybridomas, which are created by the fusion of an antibody-producing spleen cell and a 
myeloma cell, are capable of producing monoclonal antibodies against almost any existing 
antigen (Kohler and Milstein, 1975). Once hybridomas producing a specific antibody have 
been isolated and cultured, it is necessary to scale up production in order to obtain high 
antibody yields. 
There are various methods of culturing hybridomas on an industrial scale, including 
batch, fed-batch, CSTR (continuous stirred tank reactor) and perfusion culture. Batch and 
fed-batch reactors are commonly used because they are easy to operate, but provide relatively 
low antibody yields and cannot be operated continuously. CSTR reactors operate 
continuously, but do not achieve the high cell densities and productivities that can be 
obtained in perfusion culture. In perfusion culture, cells are maintained in a low growth state 
by entrapping the cells in a reactor chamber and removing spent growth medium through a 
membrane system. Although there are some challenges in scale up, perfusion systems are 
becoming a more popular means of culturing hybridoma cells because of the higher cell 
densities and productivities that can be achieved than with other methods. Homogeneous 
perfusion has some advantages over heterogeneous systems due to localized nutrient 
limitations and buildup of dead cells, caused by cell entrapment, in heterogeneous systems. 
In homogeneous systems, fresh media is added directly to a well-mixed chamber containing 
2 
the growing cells. Spent cell-free media is removed from the reactor through membrane 
filters or by other separation devices. In heterogeneous systems, cells are entrapped in a 
polymer matrix or by a membrane system. Fresh media needs to diffuse into the system in 
order to feed the cells. 
Perfusion reactors can be operated such that fresh media is continuously added to the 
reactor, while cell-free and cell-containing bleeds are removed in order to maintain a steady 
state. As the cell bleed rate in these reactors is decreased there is an increase in viable cell 
density but in many cases, a simultaneous decrease in viability. If the cell bleed rate is 
further reduced, dead cells begin to build up in the reactor and both the viability and the 
viable cell density begin to drop rapidly. The viable cell density is the concentration of cells 
in the reactor that have an intact cell membrane, while the viability is the percentage of total 
cells that are determined to be viable. 
The buildup of dead cells that occurs at low cell bleed rates may be the result of both 
apoptosis and necrosis. Apoptosis is genetically programmed cell death in which the cell 
actively participates in the pathway to death, while necrosis is the result of a violent physical 
or chemical insult against the cell that is not regulated by intracellular signal transduction 
pathways. Apoptosis is initially characterized by cell shrinkage and condensation of the 
nuclear chromatin. This is followed by extensive nuclear fragmentation and the breakup of 
the cells into apoptotic bodies. Apoptosis can be initiated by numerous factors that include 
nutrient limitation, mechanical stress, viral infection, toxic buildup, and growth factor 
deprivation. 
Hybridoma cells grown in many culture conditions are susceptible to apoptosis (Al-
Rubeai et al., 1991; Franck and Vomastek, 1992; Singh et al., 1994). Due to the observations 
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of de la Broise et al. (1991) that cells in perfusion culture enter an arrested state and die 
quickly, it seems likely that cells in the low growth states normally found in perfusion culture 
may be susceptible to apoptosis. Even with apparent substrate availability and without toxic 
concentrations of metabolites, hybridomas held at low growth rates continue to die in 
perfusion culture (Banik and Heath, 1995). In addition, hybridomas whose growth was 
inhibited by thymidine treatment quickly died as the result of apoptosis (Perreault and 
Lemieux, 1993; Simpson et al., 1997). These results suggest that higher viable cell densities 
can be achieved at very low growth rates in perfusion culture by minimizing cell death from 
apoptosis. 
One method of blocking cell death due to apoptosis is to overexpress the 
protooncogene bcl-2. Bcl-2 has been found to block apoptosis in many cell lines, including 
hybridomas (Itoh et al., 1995; Simpson et al., 1997). It may be possible to increase the viable 
cell density of perfusion reactors by growing hybridomas that overexpress bcl-2. 
The objective of this research was to determine whether or not bcl-2 has an anti-
apoptotic effect on H166 hybridoma cells in both batch and perfusion cultures. Assuming 
that bcl-2 does prevent apoptosis in this cell line, the initial focus of this project was to 
determine if an optimal level of bcl-2 expression could be found for cell proliferation and 
antibody productivity. To examine the impact of various bcl-2 expression levels on 
hybridoma cell proliferation and antibody production, a constitutive bcl-2 expression vector 
was obtained by removing the bcl-2 cDNA fragment from pbcl2UHD (obtained from Dong 
X. Yin, Stanford University) and inserted into the multiple cloning site of pcDNA3.1/ 
hygro(-) (Invitrogen). This expression vector was used to obtain numerous bcl-2 expressing 
clones that were used throughout this study. 
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The effect of bcl-2 on hybridoma cells in batch culture was determined by growing 
cells in 250 ml spinner flasks and analyzing the cell density, IgM content and the extent of 
apoptosis. Bcl-2 content was quantitatively measured by Western blotting and was analyzed 
on a per cell basis by flow cytometry. This allowed for the effect of various levels of bcl-2 
content to be determined. The supernatant from the cultures was analyzed for glucose, 
glutamine, lactate and ammonia in order to determine if bcl-2 had any effect on cell 
metabolism, to addition, a cell cycle analysis was performed by flow cytometry in order to 
determine if protection of the cells from apoptosis was due to blocking of the cell transition 
into S phase. 
Once bcl-2 was shown to reduce the rate of cell death in batch culture, several clones 
were grown in perfusion culture in order to analyze the effect of different levels of bcl-2 
expression. Preliminary studies have shown that hybridoma cells grown in high cell 
retention perfusion culture die primarily from apoptosis, rather than from necrosis. With the 
assumption that hybridomas grown in long-term perfusion culture also die mainly as the 
result of apoptosis, it was believed that bcl-2 expression would allow the cultures to retain 
high viable cell densities and viabilities, even at low cell bleed rates. This assumption was 
studied by analyzing the bcl-2 expression levels and the steady state cell densities of various 
clones. 
This study shows the effect of different levels of bcl-2 content on hybridoma cells in 
batch culture and perfusion cultures. It examines whether the use of bcl-2 expressing clones 
is a valuable approach to increasing antibody productivities in cultures of H166 hybridoma 
cells. 
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THESIS ORGANIZATION 
This thesis consists of four chapters. Chapter 1 is a general introduction of this 
project including a thesis overview and a detailed literature review of related papers. 
Chapters 2 and 3 are the manuscripts of papers to be submitted for publication. Chapter 4 is 
a general conclusion that ties the manuscripts together and discusses the importance of the 
results. In addition, appendices are included that show additional work performed that was 
not included in either of the manuscripts. 
LITERATURE REVIEW 
Hybridoma cells and antibody production 
Antibodies or immunoglobulins are glycoproteins consisting of two identical light 
chains and two identical heavy chains, which associate through disulfide bonds. Production 
of monoclonal antibodies by the immune system is triggered in response to the presence of 
foreign molecules such as proteins, carbohydrates and nucleic acids, known as antigens. In 
the immune response, antibodies function by binding to specific antigens and marking them 
for elimination. 
Antibodies are useful in the detection and purification of many biological products, 
such as proteins, nucleic acids, and carbohydrates, because of the specificity of the antigen-
antibody interaction. In addition, antibodies have found use as therapeutic agents in areas 
such as cancer research. As a result, there is a increasing demand for large quantities of 
highly purified monoclonal antibodies and much effort has been directed towards finding 
cheap and efficient ways of producing them. 
Initially, antibodies were obtained from immunized animals, such as rabbits and 
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goats. The animals were bled in order to obtain serum containing the antibody of interest 
This method proved to be very inefficient and expensive. The serum isolated from the 
immunized animals contained a mixture of antibodies, other than the antibody of interest, 
which could interfere with the antibody's intended use. The mixture of antibodies could bind 
to a wide range of antigens, resulting in difficulties in detection. The mixture may also be 
difficult to purify and may be immunogenic if used for therapy. Also, the production of 
antibody was not constant for a specific animal and production could not be controlled. With 
advances in technology, it became necessary to find a way to produce highly purified 
monoclonal antibodies. 
In 1975, Kohler and Milstein developed a technique for developing cells that could 
produce monoclonal antibodies against a specific antigen that could be grown continuously 
in culture. It is not possible to clone a single lymphocyte cell to produce monoclonal 
antibodies because lymphocytes will not grow continuously in culture. Kohler and Milstein 
took mouse myeloma cells and fused them to lymphocytes isolated from the spleen of an 
immunized mouse. These hybrid cells, known as hybridomas, were grown in selection media 
and clones were isolated. It is now possible to obtain a virtually unlimited supply of 
monoclonal antibodies against almost any foreign antigen. 
The use of hybridomas to produce antibody is one of the most common ways of 
producing large amounts of monoclonal antibodies today. Hybridomas are typically grown 
in batch or fed-batch culture, but recent technological advances have increased the demand 
for monoclonal antibodies. There is a need to find more efficient ways of producing 
monoclonal antibody that can be scaled up as demand increases. 
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Culturing of hybridoma cells 
Hybridoma cells can be cultured in batch, CSTR and perfusion cultures for 
production of monoclonal antibodies. Initially, monoclonal antibodies were primarily 
cultured in batch reactors because they are easy to operate. Most of the research in this area 
focused on improving culture conditions to increase cell densities and improve cell survival 
(Low and Harbour, 1985; McQueen and Bailey, 1989; Heath et al., 1990; Duval et al., 1991). 
Low and Harbour (1985) investigated the use of various glucose concentrations on 
hybridoma growth and found that increased glucose concentrations led to significantly 
increased cell densities and increased antibody yields. Luan et al. (1987) investigated the 
effect of various glucose/glutamine ratios and found that both cell growth and specific 
antibody production rates were constant over a large range of glucose/glutamine ratios. 
Heath et al. (1990) showed that a reduction in serum content actually increased specific and 
volumetric antibody production rates, until cell densities dropped due to serum deprivation at 
0.5% FBS (fetal bovine serum). Due to the expense of serum and difficulties that serum can 
cause in antibody purification, it is advantageous to use as little serum as possible. Other 
factors affecting hybridoma growth and monoclonal antibody productivity were also 
investigated, such as oxygen requirements (Boraston et al., 1997), the effect of ammonia and 
pH (McQueen and Bailey, 1989), and the influence of the amino acid supply (Duval et al., 
1991). 
Soon investigators began to focus their efforts on understanding the cellular 
metabolism of various cell lines in order to shift cell metabolism to obtain higher cell 
densities and increase specific antibody production rates (Lanks and Li, 1988; Al-Rubeai and 
Emery, 1990; Ozturk and Palsson, 1991; Mancuso et al., 1994). Ozturk and Palsson (1991) 
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found that cell growth stopped when glutamine in the media was depleted, and that glucose 
could not substitute for this glutamine depletion. In addition, they found that the cells obtain 
about 45% of their energy from glycolysis, with the remainder generated by oxidative 
phosphorylation. The specific antibody production rates remained constant during the 
exponential and decline phases of cell growth, although intracellular antibody content 
decreased during the decline phase. Flow cytometry was used to determine the antibody 
productivity of cells at different points in the cell cycle (Ramirez and Mutharasan, 1990; Al-
Rubeai et al., 1991). Ramirez and Mutharasan (1990) found that cells in the G1 phase 
secreted monoclonal antibody at a faster rate than in other phases of the cell cycle. Al-
Rubeai and Emery (1990) confirmed these findings by arresting cells in the Gl/S phase by 
treatment with thymidine. In addition, Simpson et al. (1999) found that the percentage of 
cells in G1 phase increased with a decrease in both the dilution rate and specific growth rate 
in continuous culture. These results suggest that restricting cells to low growth rates, such as 
those seen in perfusion culture, could lead to an increase in specific antibody productivity. 
Others have investigated the use of fed-batch systems to increase cell density and 
monoclonal antibody productivity (Omasa et al., 1992; Kurokawa et al., 1994; Zhou et al., 
1997). A fed-batch reactor is operated such that media can be added at intervals throughout 
the culture period, but nothing is removed until the end of the process. Kurokawa, et al. 
(1994) found that when glucose and glutamine were controlled at 0.2 and 0.1 g/1, 
respectively, the cell concentration and antibody production nearly doubled compared to 
reactors controlled at higher concentrations of both nutrients. The ability to control nutrient 
and metabolite concentrations throughout a run allows for greater viable cell densities and 
antibody production than batch cultures. Fed-batch reactors are attractive to industry because 
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the setup and operation are similar to that of batch reactors. 
One of the drawbacks of batch and fed-batch systems is that operation is not 
continuous and the startup and shutdown phases incur significant cost and time. An 
alternative is to operate in continuous or semi-continuous culture, where medium is 
continually supplied to and removed from the chemostat. Many investigators have examined 
the nutrient limitations in chemostat cultures, which are steady-state continuous cultures 
without cell retention (Miller et al., 1988; Hiller et al., 1991; Jan et al., 1997). The goal of 
this research was to examine the nutrient and metabolite limitations and possibly increase the 
viable cell density in these reactors. In a chemostat, the viability and viable cell density 
reach a maximum at an intermediate dilution rate, which is somewhat cell line dependent. 
An optimal dilution rate of approximately 0.6 volumes/day was found for a VX-7 hybridoma 
by Ray et al. (1989), and resulted in a viable cell density of greater than 2 x 106 cells/ml. A 
typical maximum cell density for hybridomas grown in a chemostat is 1-3 x 106 viable 
cells/ml (Ray et al., 1989; Hiller et al., 1993; Banik and Heath, 1995; Jan et al., 1997), which 
in some instances can be reached in the absence of nutrient deprivation. Achieving larger 
viable cell densities than obtained in chemostat cultures could allow for greater antibody 
productivity. In order to accomplish this, concentrating the cells inside the chemostat was 
the next logical approach. 
Perfusion systems provide many advantages for large-scale production of monoclonal 
antibodies. They can provide increased yield on medium use, easy monitoring and control of 
culture conditions, absence of nutrient and metabolite gradients, and ease of scale up. 
Homogeneous perfusion was first achieved by incorporating a spin filter into a standard tank 
(Schmialek, 1976). A homogeneous system allows for mixing of media such that all cells are 
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subjected to identical conditions, where hetereogeneous systems lead to component 
gradients. Other methods of obtaining homogeneous perfusion include the use of dialysis 
perfusion (Amos et al., 1994), recirculation through internal microporous polypropylene 
fibers (Banik and Heath, 1994), external centrifuges (Tokashiki et al., 1990), internal 
membrane filters (Reuveny et al., 1986), inclined settlers (Searles et al., 1994), external 
hollow fiber membranes (de la Broise et al., 1991; Hiller et al., 1993), and acoustic systems 
(Bierau et al., 1998). Methods for obtaining heterogeneous perfusion include entrapment in 
alginate beads and entrapment in the extracapillary space of a hollow fiber cartridge (de la 
Broise et al., 1991). 
De la Broise et al. (1992) compared a homogeneous perfusion reactor using an 
external hollow fiber membrane and two heterogeneous perfusion reactors. In one reactor, 
cells were entrapped in alginate beads, while in the other, cells were entrapped in the 
extracapillary space of a hollow fiber cartridge. The results showed that the steady state cell 
concentration and antibody productivity were similar regardless of the method of obtaining 
perfusion. Heterogeneous perfusion systems have the disadvantage of difficulty in scale up, 
diffusion limitations and buildup of dead cells. Homogeneous perfusion systems are a much 
more attractive option for the long-term culture of mammalian cells. 
In an earlier study, de la Broise et al. (1991) found that hybridomas grown in 
perfusion culture represent a "grow or die" system. This means that if the cell bleed rate is 
reduced to the point where cells are not permitted to grow, the viability of the reactor will 
quickly drop, even without nutrient depletion. Banik and Heath (1995), among others, 
confirmed this result. As the growth rate is decreased, dead cells begin to build up in the 
bioreactor. The cells are unable to utilize available substrate and die rapidly. It is possible 
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that this arrested state and the buildup of dead cells may be related to apoptosis. 
Banik and Heath (1995) used microporous polypropylene fibers coiled inside a 
reactor in order to achieve perfusion, and were able to achieve cell densities as high as 2 x 
107 viable cells/ml. They found that the specific antibody production rate was strongly 
correlated with viable cell density. The specific antibody production rate increased with cell 
density, and was independent of growth rate for the cell line studied. Substrate metabolism 
became more efficient at high cell densities and low specific growth rates. These shifts in 
metabolism are strong indications of the production potential of high cell density perfusion 
culture. 
One potential problem that may be encountered in a perfusion reactor system is the 
fluctuation of viable cell density with time (Vits and Hu, 1992). In some cultures, the viable 
cell density remains constant with time, while in others there is a slow downward drift in 
viability without an apparent steady state. Others have shown appreciable fluctuations in the 
viable cell density that continues throughout the culture period. The fluctuations may cause 
great problems in controlling production. The model of Vits and Hu (1992) suggests that 
small fluctuations in the retention ratio, the ratio of cell bleed to the dilution rate, may 
dramatically affect cell density. These small fluctuations may make obtaining true steady 
state a difficult task, and much care needs to be taken to eliminate these fluctuations. 
In comparing perfusion reactors to other reactor types, the advantages of perfusion 
become readily apparent. Reuveny et al. (1986) achieved cell densities as high as 2.2 x 107 
viable cells/ml in a perfusion culture using an internal membrane filter device. In batch and 
fed-batch operation, viable cell densities only reached 1-2 x 106 viable cells/ml, while in a 
semi-continuous system viable cell densities were as high as 2.4 x 10* viable cells/ml. In the 
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fed-batch system, a spinner flask initially contained 60 ml of media, with 6 ml added to the 
reactor each day, while the semi-continuous culture consisted of a 100 ml spinner flask with 
a feed rate of50-400 ml/1 culture per day. The benefit of perfusion can really be seen when 
the productivities of the cultures are compared. The perfusion reactor had a monoclonal 
antibody productivity of660 mg/1 culture per day, while batch, fed-batch and semi-
continuous cultures had productivities of 15,27 and 34 mg/1 culture per day, respectively. 
Importance of apoptosis in cell death 
Apoptosis is a type of cell death in which cells actively participate. It has been 
recognized for years that some instances of cell death are the result of an internal cellular 
program (Glucksmann, 1952). This type of cell death, in which cells undergo a distinct set of 
structural changes, was first identified as shrinkage necrosis (Kerr, 1971). The term 
apoptosis, which is synonymous with programmed cell death, was first introduced by Kerr et 
al. (1972). Apoptosis plays a major role in cell population control during early development, 
as seen in the case of Caenorhabditis elegans. It has also been suggested that the loss of the 
ability to regulate apoptosis may play a role in both cancer and AIDS (Trauth et al., 1989; 
Ameisen, 1992; Finkel et al., 1995). 
The characteristic features of apoptosis can be divided into three parts. Initially, 
apoptosis is identified by condensation of the chromatin into crescent shaped caps at the 
nuclear periphery, disintegration of the nucleoli, and reduction in the nuclear size. This is 
accompanied by shrinkage of the total cell volume, compaction of the cytoplasmic 
organelles, and dilation of the endoplasmic reticulum. During the early stages of apoptosis 
the gross structures of the mitochondria are relatively unaffected. Next, there is a period of 
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cell surface membrane blebbing accompanied by constriction of the nucleus and cytoplasm 
into small membrane bound apoptotic bodies. This is followed by the progressive 
breakdown of the residual nuclear and cytoplasmic structure, which is sometimes referred to 
as secondary necrosis. At this point, it becomes difficult to distinguish apoptotic from 
necrotic cells. In tissues, the apoptotic cell bodies are phagocytized by viable neighboring 
cells or by specialized phagocytes. In this way, the toxic metabolites of the dying cells are 
not released directly into the tissue. The entire process of apoptosis lasts only a period of a 
few hours. The early changes in an apoptotic cell, up until the formation of apoptotic bodies, 
may be visible for only a few minutes in tissue (Bursch et al., 1990). Figure 1 shows the 
morphological changes that a cell undergoes during both apoptosis and necrosis. 
The morphological changes that occur during apoptosis are accompanied by 
numerous biochemical changes. During the course of apoptosis, the nuclear DNA is broken 
down into 50-300 kb size fragments (Arends et al., 1990; Oberhamner et al., 1993). This is 
followed by further DNA degradation into low molecular weight fragments of 180 bp 
multiples. These fragments result in the DNA ladder formation that is characteristic of 
apoptosis when run on an agarose gel (Wyllie et al., 1980; Duke et al., 1983). The 
cytoplasmic proteins become highly cross-linked as the result of the increased levels of tissue 
transglutaminase seen in apoptotic cells (Fesus et al., 1989; Piacentini et al., 1991). In 
addition, phosphatidyl serine shifts to the outer leaflet of the plasma membrane (Castedo et 
al., 1996). Some other changes that occur in apoptotic cells are an increase in Ca+2 content, a 
decrease in K+, an increase in non-oxidized glutathione, an increase in the reactive oxygen 
species, and a change in the mitochondrial transmembrane potential (Zamzami et al., 1995; 
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Aooptosis 
Condensation of the chromatin into 
crecent shaped caps, shrinkage of the 
cell volume, mitochondria unaffected 
membrane blebbing, constriction of 
the nucleus into apoptotic bodies 
» 
© 
Necrosis 
e 
e 
The cell breaks up into apoptotic bodies, DNA 
collapses into numerous spherical masses 
Cells and organelles 
become swollen 
0 
Organelles eventually lyse and the 
cell membranes begin to break-up 
Figure 1. Comparison between the morphological changes that occur in apoptosis and 
necrosis. 
Petit et al., 1995; Macho et al., 1997). 
Apoptosis is distinctly different from necrosis, which is the result of extreme changes 
in the cellular environment. Necrosis is characterized by swelling of the dying cells and 
internal organelles, while the general structure of the chromatin is maintained. Cell swelling 
is followed by rupture of the plasma membrane, and release of internal contents into the 
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extracellular space. In tissues, this release may result in inflammation. In vitro, it may be 
difficult to distinguish between apoptotic and necrotic cells because the membranes of late 
stage apoptotic cells eventually become permeable and release cellular components into the 
extracellular space. 
The term apoptosis was originally used to describe cell death that differs from 
necrosis on a morphological basis (Kerr et al., 1972), that is observable by light or electron 
microscopy. Various experimental techniques have since been used to identify apoptosis. 
Many of these techniques involve staining the cells and observing the cell morphology using 
fluorescence microscopy. In these tests, the DNA is stained using dyes such as propidium 
iodide and acridine orange. Acridine orange can permeate all of the cells and results in green 
staining, while cells with membrane damage are stained red by propidium iodide. Apoptotic 
cells are identified by looking for condensation of the chromatin and formation of apoptotic 
bodies that are hallmarks of apoptosis (Singh et al., 1994; Mercille and Massie, 1994a). In 
addition, the degradation of DNA into fragments of 180 bp multiples can be used to confirm 
cell death by apoptosis. These low molecular weight DNA fragments are run on an agarose 
gel to view the DNA ladder which is characteristic of apoptosis (Wyllie, 1980; Duke, 1983). 
Another method to identify DNA fragmentation is to label the DNA strand breaks. The 3'-
OH termini in the DNA strand breaks are labeled with biotin, digoxygenin- or fluorescein-
conjugated nucleotides in a reaction catalyzed by exogenous terminal deoxynucleotidyl 
transferase (Gorczyca et al., 1993). Apoptotic cells are then identified by light microscopy or 
flow cytometry. The amount of mitochondrial DNA can also be compared to the amount of 
nuclear DNA to determine the level of apoptosis (Tepper and Studzinski, 1993). The amount 
of mitochondrial DNA remains relatively constant during the initial stages of apoptosis, 
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while the amount of nuclear DNA drops off. In addition, annexin V conjugated to FITC can 
be used to identify apoptotic cells. The annexin V binds to the phosphatidyl serine that flips 
to the outer leaflet of the plasma membrane when a cell enters apoptosis. Apoptotic cells can 
then be identified by fluorescence microscopy or flow cytometry (Vermes et al., 1995; 
Ishaque and Al-Rubeai, 1998). 
Initially, investigators believed that RNA or protein synthesis was necessary for the 
induction of apoptosis (Wyllie et al., 1984). Later, it was determined that cells can enter 
apoptosis in the absence of gene expression (Eastman et al., 1994). These cells were thought 
to be primed for apoptosis. Apoptosis can be caused by numerous environmental factors. A 
growth factor may result in apoptosis when accompanied by nutrient limitation. Apoptosis 
may occur as the result of injury to the cell membrane, mitochondrial injury, cytotoxic T cell 
killing and the attack of cells by viruses (Wyllie, 1997). Physiological activators of apoptosis 
include tumor necrosis factor, loss of matrix attachment, calcium, and glucocorticoids 
(Thompson, 1995). Apoptosis may occur in response to DNA breaks caused by ionizing 
radiation. In addition, apoptosis can be caused by chemotherapeutic drugs, such as 
doxorubicin, cytosine arabinoside, and methotrexate. Various proteins have been implicated 
as having a pro-apoptotic function including the following: interleukin-1B-converting 
enzyme, p53, ced-3, c-myc, bax and c-fos. Anti-apoptotic proteins include ced-9, crmA, bag, 
bcl-2 and other bcl-2 related proteins. 
Many instances of cellular injury can occur in bioreactors as a result of shearing 
forces, temperature, pH changes and other factors. In extreme cases, these injuries can lead 
to cell death by necrosis, while in other situations they lead to cell death via apoptosis. In 
cell cultures, apoptosis may be caused by many factors including the toxic buildup of 
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metabolites, oxygen limitation, withdrawal of growth factors, heat shock, viral infection, and 
nutrient limitation (Thompson, 1995; Singh et al., 1996). By preventing the cells from 
undergoing apoptosis, it may be possible to increase the viability and viable cell density in 
mammalian bioreactors. 
Role of bcl-2 In preventing apoptosis 
In recent years, it has become apparent that bcl-2, along with other related proteins, 
plays an important role in the control of apoptosis. Bcl-2 was first identified by Tsujimoto et 
al. (1985). They found that bcl-2 expression was altered in a majority of B-cell follicular 
lymphomas by a chromosomal translocation, t(14;18). The translocation places the gene in 
close proximity to the enhancer elements of the immunoglobulin heavy chain (IgH) resulting 
in deregulated bcl-2 expression (Tsujimoto et al., 1987). 
The bcl-2 proto-oncogene is encoded by a gene 230 kb in size that gives rise to a 22-
26 kDa protein. Bcl-2 belongs to a large family of proteins that are known to influence 
apoptosis. Bcl-2, bcl-xt, bfl-1, mcl-1 and others inhibit apoptosis, while bax, bak, bcl-xs and 
others stimulate apoptosis. Many proteins in the bcl-2 family, including bcl-2 itself, are 
localized to the outer mitochondrial membrane, but may also be found in the nuclear 
membrane and the endoplasmic reticulum (Krajewski et al., 1993; Gotow et al., 2000; Annis 
et al., 2001). Bcl-2 contains a carboxy-terminal transmembrane region that targets the 
protein to the mitochondria, and only bcl-2 targeted to the mitochondria is effective in 
preventing cell death. In a study of human leukemia cells, Jia et al. (1999) suggested that the 
level of bcl-2 expression in the mitochondria might determine the sensitivity of these cells to 
apoptosis. 
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Although the exact mechanism of bcl-2 involvement in regulating cell death is still 
unclear, it has been suggested that bcl-2 located in the mitochondria may block the release of 
cytochrome c (Kluck et al., 1997; Yang et al., 1997). Yang et al. (1997) determined that 
overexpression of bcl-2 in HL-60 cells prevented the release of cytochrome c into the cytosol 
and delayed the initiation of apoptosis. It was later found that bcl-2 and the other bcl-2 
family members regulate the permeability of the inner and outer mitochondrial membranes 
through the transition pore (PT) and the voltage-dependent ion channel (VDAC) (Harris et 
al., 2000; Tsujimoto et al., 2000). Bcl-2 through cytochrome c and other apoptogenic factors 
appears to prevent the activation of various caspases, a family of cysteine proteases that are 
activated in the apoptosis cascade (Green and Reed, 1998). These caspases are directly 
responsible for the breakdown of specific proteins and for the morphological and 
biochemical cell changes that occur during apoptosis. Other proteins known to interact with 
bcl-2 in the prevention of apoptosis include raf-1, bag-1, and ced-4. The ced-9 gene of C. 
elegans has similar biological activity to that of bcl-2, and has some sequence homology 
(Vaux et al., 1992). 
The bcl-2 gene was first shown to prolong cell survival by blocking apoptotic cell 
death. Vaux et al. (1988) showed that bcl-2 expression was able to prolong cellular survival 
of IL-3 dependent B and myeloma cell lines after depletion of IL-3. Since B cell hybridomas 
are formed by the fusion of a B cell and a myeloma cell, this research suggests that bcl-2 may 
also protect hybridomas from apoptotic cell death. 
In a study of growth factor deprived hemopoietic cell lines, Nunez et al. (1990) 
determined that bcl-2 protection from apoptosis appears to be cell line or growth factor 
dependent. Bcl-2 extended the lives of IL-3 dependent pro B-lymphocytes subjected to 
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growth factor withdrawal, but failed to protect either an IL-2-dependent T cell line or an IL-6 
dependent myeloma cell line. 
Miyashita and Reed (1993) determined that bcl-2 confers resistance to chemotherapy 
induced apoptosis in a human leukemia cell line. Cells that were modified to express bcl-2 
had an increased resistance to treatment with drugs used in chemotherapy such as 
dexamethasone, methotrexate, and etoposide. 
Singh et al. (1996) looked at the effect of bcl-2 on the growth of Burkitt's Lymphoma 
cells and found that there was a reduction of both the total cell death rate and the level of 
apoptosis occurring in the decline phase of stationary batch cultures. In addition, a bcl-2 
transacted cell line survived longer than control cultures when treated with thymidine to 
arrest cell growth. This indicates that bcl-2 may limit cell death at the low growth rates 
typically seen in perfusion reactors. In addition, they found that the bcl-2 transacted cell 
line survived much better in numerous types of serum- and protein-free media than control 
cultures. Lee and Shacter (1997) found that bcl-2 could not protect Burkitt's Lymphoma 
cells from oxidant induced cell death, although it was effective in protecting the cells from 
apoptosis induced by agents such as the calcium ionphore A23187. These results suggest 
that bcl-2 may protect cells from some causes of apoptosis, while it is ineffective against 
others. This may become important in cultures subjected to numerous potential causes of 
apoptosis. 
Murray et al. (1996) examined an NSO myeloma cell line and found that 
overexpression of bcl-2 failed to delay the onset of cell death during batch culture. In 
addition, the overexpressed bcl-2 appeared to have no anti-apoptotic effect in response to 
serum limitation. Since NSO myeloma cells are commonly used in the formation of B cell 
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hybridomas, it is possible that these hybridomas may also fail to show an anti-apoptotic 
effect due to the overexpression of bcl-2. B cell hybridomas developed from myeloma cells 
that express bcl-2 should be investigated in order to determine if bcl-2 production and 
function are maintained. In order to explain the lack of an anti-apoptotic effect, Murray et al. 
found that the NSO cell line naturally expresses bax and bcl-xu Bax hetereodimerizes with 
bcl-2 to cancel the anti-apoptotic effect in an IL-3 dependent cell line (Oltvai et al., 1993), 
while bcl-XL has been found to have a similar function to bcl-2. It is possible that the bcl-2 
effect is either canceled out by bax or that bcl-2 is redundant in NSO myeloma cells. 
In contrast, Schwarze and Hawley (1995) found that bcl-2 was able to suppress 
apoptotic cell death following IL-6 deprivation in IL-6-dependent B9 myeloma cells at high 
levels of gene expression. They determined that bcl-2 was able to counteract the effects of 
the endogenous bax protein present in the cells. In the absence of IL-6-deprivation, the up-
regulation of endogenous bcl-xt prevented apoptosis in the B9 myeloma cells. These results 
suggest that the level of gene expression may be important in the prevention of apoptosis in 
cell lines that produce endogenous bcl-2 related proteins. 
In addition to bcl-2, other bcl-2 related genes regulate apoptotic cell death. 
Alternative splicing results in two forms of bcl-x. BC1-XL inhibits cell death upon growth 
factor withdrawal in an IL-3 dependent cell line, while bcl-xs inhibits the ability of bcl-2 to 
prevent apoptotic cell death (Gibson et al., 1996). In vivo, bcl-xs is found in fast growing 
cells, while bcl-XL is prevalent in long-lived post-mitotic cells. This suggests that proteins 
like bcl-2 and bcl-XL may support cell survival in conditions of low cell turnover, such as 
seen in high cell retention perfusion reactors. In addition to bcl-xs, overexpression of bax, 
which has extensive homology to bcl-2, accelerates apoptosis induced by cytokine 
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deprivation in an EL-3-dependent cell line. Bax counters the anti-apoptotic function of bcl-2 
in vivo by forming heterodimers with bcl-2 (Oltvai et al., 1993). In addition to proteins 
which show significant homology to bcl-2, proteins such as bag-1 have been shown to 
increase the anti-apoptotic effect of bcl-2 (Takayama et al., 1995). Activation of the c-Jun N-
terminal kinase also counters the anti-apoptotic effect of bcl-2 (Park et al., 1997). 
Although the mechanism of the anti-apoptotic activity of bcl-2 is unclear, it has been 
determined that DNA fragmentation or the synthesis of new RNA and protein are not 
necessary for either apoptosis to occur (Eastman et al., 1994), or for the anti-apoptotic effect 
of bcl-2 (Jacobson et al., 1994). Jacobson et al. showed that the bcl-2 function still remains 
even in the absence of a nucleus. Ito et al. (1997) showed that bcl-2 phosphorylation is 
required for the anti-apoptotic function. In this study, the protein kinase C phosphorylation 
sites of bcl-2 were altered by conservative serine/alanine mutations. These sites could no 
longer be phosphorylated and the mutant protein was unable to prolong cell survival in 
murine IL-3 dependent NSF/N1.H7 cells. 
In addition to constitutive expression systems, Yin and Schimke (1995) developed a 
double stable cell line using the tet-off gene expression system in order to obtain HeLa S3 
cells with inducible on/off bcl-2 control. In these studies, they were able to obtain a 100-fold 
induction of bcl-2 in the absence of tetracycline. The level of induction was confirmed by 
Western blotting. Bcl-2 clones were grown in the presence of various levels of tetracycline 
for two days in batch culture and were then treated with 2 jig/ml aphidicolin in order to 
induce apoptosis. The extent of apoptosis was determined by staining with propidium iodide 
and counting cells that showed apoptotic morphology under a fluorescence microscope. 
They determined that when protection from apoptosis was plotted against the amount of 
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bcl-2, a hyperbolic relationship was revealed. As the level of bcl-2 increased, so did the 
percentage of non-apoptotic cells. Lin et al. (1997) obtained inducible expression of bcl-2 by 
the lac operator/repressor system in MDCK cells. Isopropyl-(3-D-thiogalactosidase (IPTG), 
added to the cells, binds the repressor and induces bcl-2 expression. They found that bcl-2 
expression conferred partial or total resistance to cell death. 
Apoptosis in hybridoma cells 
Several investigators have looked at hybridoma cells in both batch and continuous 
culture to determine if apoptosis is a major cause of cell death. An electron microscopic 
study by Al-Rubeai et al. (1991) suggested that spontaneous apoptosis occurs in B cell 
hybridomas. Franek and Vomastek (1992) observed that fragmented DNA and apoptotic 
bodies were prevalent during the late stationary phase in batch cultures of hybridoma cells, 
indicating that apoptosis represents a prevalent mode of cell death. Using gel 
chromatography, they determined that 30% of the DNA was fragmented in the late stationary 
phase compared to less than 5% on day zero. In addition, other investigators have noted 
spontaneous apoptosis occurring in B cell hybridoma cultures even under normal culture 
conditions (Vomastek and Franek, 1993; Mercille and Massie, 1994a; Solis-Recendez et al., 
1995; Chung et al., 1997). 
The induction of apoptosis normally requires de novo gene expression, but certain 
cell types, including hybridomas, have undergone apoptosis after gene expression had been 
blocked. Perreault and Lemieux (1993) found that apoptosis occurred in a matter of 2-4 
hours in SP2/0-derived hybridoma cells after treatment with either cycloheximide or 
actinomycin D, which are inhibitors of protein synthesis or transcription, respectively. They 
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also tested a random set of hybridomas and found that the susceptibility of hybridomas to 
cycloheximide induced apoptosis varied with the myeloma fusion partner. This result 
indicates that different hybridoma clones may have varying degrees of susceptibility to 
different types of apoptosis inducers. 
In contrast, Liu et al. (1994) studied murine EL-6-dependent B-cell hybridoma 7TD1 
cells in order to investigate the anti-apoptotic effect of IL-6. Cells were cultured in the 
presence of cycloheximide, an inhibitor of protein synthesis or ATA, a DNA endonuclease 
inhibitor, with or without IL-6 supplementation. It was determined that inhibition of 
apoptosis required de novo protein synthesis and that apoptosis could be prevented by 
blocking DNA fragmentation. These results suggest that some inducers of apoptosis may 
require de novo gene expression, while others do not. 
Singh et al. (1994) investigated the incidence of apoptosis in a variety of cell lines to 
determine which cells were susceptible to apoptosis and what were the major causes of 
apoptosis. In batch cultures of hybridoma TB/C3 and plasmacytoma cells, they found that 
60-90% of all dead cells were apoptotic, while Chinese hamster ovary cells and SF9 insect 
cells did not appear to die from apoptosis. The most effective inducers of apoptosis were 
glutamine-, serum- and glucose-deprivation, followed by ammonia toxicity. In addition, 
blockage of the cell cycle by thymidine resulted in the induction of apoptosis in both 
hybridoma and plasmacytoma cells. This suggests that limiting or restricting cell growth 
rates that occur in perfusion reactors may result in the induction of apoptosis. These results 
are in agreement with the findings of de la Broise et al. (1991), who observed that long term 
perfusion culture represents a "grow or die" cell system. Cells grown at the reduced growth 
rates seen in perfusion culture may begin to die, presumably by apoptosis. 
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Mercille and Massie (1994b) observed that apoptosis was a prevalent mode of cell 
death in SP2/0-derived hybridoma D5 cultures subjected to oxygen limitation. They found 
that after 45 h in batch culture under anoxic conditions the cell viability decreased by 30%, 
and that 90% of these cells were determined to be apoptotic by acridine orange/ethidium 
bromide staining. Cells subjected to anoxic conditions for less than 29 h, that were then 
returned to normal conditions showed no sign of apoptosis. In addition, in an earlier study 
they found that glutamine-, cysteine- or glucose-deprivation induced apoptosis in both 
hybridoma and NSO myeloma cell lines, while metabolite accumulation of both lactic acid 
and ammonia resulted in necrotic cell death (Mercille and Massie, 1994a). 
Another possible source of cell death in stirred hybridoma cultures is intensive 
agitation. Al-Rubeai et al. (1995) found that at a low energy dissipation rate of 1.5 W/m3 
(100 rpm) there was no apparent cell damage, while at 320 W/m3 (600 rpm) cell viability 
decreased with an increasing number of cells showing signs of apoptosis. At an even greater 
energy dissipation rate of 1870 W/m3 (1500 rpm), the cell number dropped quickly by 50% 
and a population of smaller cells emerged. A large proportion of viable and non-viable cells 
appeared to show signs of apoptosis. In addition, a greater proportion of S and G2 cells had 
become apoptotic as compared to G1/G0 cells. In a perfusion reactor there are many sources 
of agitation, including stirring, gas sparging and recirculation, that could possibly lead to cell 
death by apoptosis. 
An increase in temperature may also lead to an increase in the extent of apoptosis in 
hybridoma cultures. Nagarathnamma et al. (1997) found that exposure of CC9C10 
hybridomas to temperatures of 42°C for 1 h increased the apoptosis index by 32%. It was 
also determined that increasing the glutamine concentration to 2 mM reduced the amount of 
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apoptosis at elevated temperatures. 
Investigators have found that medium supplementation may decrease cell death due 
to apoptosis. Franek et al. (1995) found that supplements of both essential and non-essential 
amino acids to the growth media could prevent apoptosis in hybridoma cells grown in 
nutrient limiting conditions in the absence of cell metabolites. They also found that 
glutamine had a less significant effect on preventing apoptosis, but resulted in an increase in 
antibody production. Chung et al. (1997) found an extension of SP2/0 hybridoma cell 
viability through interleukin-6 supplementation, especially in cultures grown with low serum 
concentrations. 
Effect of bcl-2 overexpression on hybridoma cells 
Investigators have begun to look at whether the overexpression of bcl-2 in hybridoma 
cells has an anti-apoptotic effect. Itoh et al. (1995) introduced human bcl-2 DNA into mouse 
hybridoma 2E3 cells using the BCMGSneo vector that provided for high expression of bcl-2, 
as confirmed by Western blotting. They found that the overexpression of bcl-2 increased the 
maximum viable cell density by 45%, delayed the start of apoptosis by 2 days, and prolonged 
the viable culture period by 4 days in batch culture. They also found that antibody 
production increased by a factor of four compared to cultures that were transfected with the 
BCMGSneo vector alone. The increased culture period and the increased productivity 
provide significant incentive for expressing bcl-2 in batch cultures of hybridoma cells. 
Itoh et al. (1995) also attempted to determine the effect of different levels of bcl-2 
expression on hybridoma cell survival. In addition to transfecting cells with a construct 
containing bcl-2 under the control of a cytomegalovirus promoter (CMV), they also 
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transfected cells with a construct utilizing a mouse mammary tumor virus promoter 
(MMTV). This allows for inducible expression of bcl-2 by the addition of dexamethasone. 
The transfectants that contained the inducible MMTV promoter were unable to express high 
enough levels of bcl-2 to affect cell survival. 
Koseki et al. (1995) examined the effect of activin A-induced apoptosis on mouse 
hybridoma HS-5 and HS-7 cell lines that were modified for bcl-2 overexpression. They 
determined that treatment with activin A, a member of the TGFfJ superfamily, did not result 
in increased endogenous expression of bcl-2 or bax. It was initially thought that activin A 
may induce apoptosis by causing increased endogenous expression of bax, a pro-apoptotic 
member of the bcl-2 family. In addition, they found that overexpression of bcl-2 suppressed 
activin-A induced expression of bax in these cell lines. 
Terada et al. (1997a) found that hybridoma 2E3 cells transfected with bcl-2 alone 
maintained greater than 75% viability for two more days in batch culture than control 
cultures under conditions of both thymidine treatment, for arresting the cell cycle, and serum 
deprivation. When these same cells were transfected with both bcl-2 and bag-1, they found 
that cell viability was maintained for 3 days longer than control cultures. They also found 
that bcl-2/bag-l transfectants produced antibody at three times the rate of cells transfected 
with bcl-2 alone. This provides evidence that bcl-2 related proteins may act by a mechanism 
different than bcl-2 itself in preventing apoptosis. 
In a separate paper, Terada et al. (1997b) determined that bcl-2 expression increased 
the length of time 2E3 hybridomas could survive in conditions of low serum content. When 
the cells were grown in Dulbecco's modified Eagle's medium alone, both the bcl-2 
expressing and control cell lines died within one day. They also determined that the addition 
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of serum to serum-starved cultures after four days in batch culture led to a 35% increase in 
viable cell density in the bcl-2 expressing cell line and no increase in the control. It is likely 
that many of the cells in the control culture had already entered apoptosis and were unable to 
resume growing in response to the addition of serum. 
Green et al. (1994) studied the proto-oncogene c-myc under conditions of activation 
induced apoptosis caused by the exposure to anti-CD3 antibody. They found that inhibiting 
the expression of c-myc by the addition of antisense oligodeoxynucleotides or transforming 
growth factor 3 led to an inhibition of apoptosis. In this same study, they found that the anti-
apoptotic effect of bcl-2 was not observed in this form of apoptosis. It appears that apoptosis 
caused by c-myc may occur upstream of the site of bcl-2 involvement. Cells are already 
committed to apoptosis. It is important to recognize that bcl-2 may inhibit some forms of 
apoptosis, while having no effect on others. 
In another study, Simpson et al. (1997) transfected TB/C3 hybridoma cells with a 
pEF bcl2-MClneopA vector to produce a cell line that overexpresses bcl-2. In batch cultures, 
they found that the overexpression of bcl-2 more than doubled the productive period, which 
was determined by dual fluorescence staining with acridine orange and propidium iodide. In 
addition, there was an increase of monoclonal antibody production of nearly 40% when 
compared to the control cell line. It was also found that bcl-2 extended cell integrity in 
conditions of hypoxia, hyperoxia, glutamine deprivation, glucose deprivation, and serum 
deprivation. 
Simpson et al. (1997) also suggests that cells modified for bcl-2 expression adjust to 
semicontinuous culture more easily than control cultures. The control cell line dies out after 
an increase in the feeding interval, while the transfected culture continues to proliferate. 
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From the data, it appears that the control cell line grew to higher cell densities prior to the 
increase in the feeding interval. This caused an increased initial cell density, compared to the 
bcl-2 expressor, that may have led to an increased nutrient consumption and an earlier entry 
into apoptosis. This led to a decrease in the initial seeding density from which the cells were 
unable to recover. They also found that treatment with thymidine, which suppresses cell 
proliferation, led to an increase in membrane intact cell density and specific antibody 
productivity in cells that overexpress bcl-2. These results suggest that the overexpression of 
bcl-2 may allow hybridomas to be grown at low growth rates, such as seen in perfusion 
culture, without invoking cell death. 
Simpson et al. (1998) showed that bcl-2 expression protects hybridoma cells from cell 
death caused by amino acid deprivation. Cells were deprived of each of the essential amino 
acids for 48 h and it was determined that bcl-2 expression decreased the level of apoptosis in 
each case. The viability of the bcl-2 transfectants remained above 70% after 48 h of amino 
acid deprivation, while in many cases the viability of the control cell line dropped 
significantly below 10%. Fassnacht et al. (1998) looked at the effect of bcl-2 on TB/C3 
hybridoma cell growth in serum-supplemented, protein-free and diluted media, and found 
that bcl-2 protected the cells from apoptosis in all instances. The anti-apoptotic effect was 
greater in protein free media than in media containing 3% serum. 
Chung et al. (1998) studied a CRL-1606 hybridoma in serum-containing, serum-free 
and growth factor depleted media. They found that bcl-2 expression protected the cells from 
apoptosis in cultures with low or no serum content They also found that the extent of 
protection from apoptosis was much more evident in serum free cultures that also lacked 
insulin, transferrin or L-glutamine. There was little or no evidence of protection from 
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apoptosis in cultures that contained 5% serum. These results confirm the results of Fassnacht 
et al. (1998) and indicate that the anti-apoptotic effect of bcl-2 may be most important in 
growth factor deprived cultures. 
Most research to this point has focused on the effect of bcl-2 expression on batch, 
fed-batch or semicontinuous systems. Bierau et al. (1998) investigated the effect of bcl-2 on 
hybridoma proliferation in perfusion culture with nearly total cell retention. Cell retention 
was obtained by using either a spin filter or ultrasonic filter. Using a TB/C3 hybridoma cell 
line they determined that bcl-2 expression resulted in an increase in the viable cell density 
and viability, but little change in volumetric antibody productivity. This is in contrast to the 
results in batch culture where volumetric antibody productivity was significantly increased 
(Simpson et al., 1997). The ultrasonic filters allow for slightly higher retention of viable 
compared to non-viable cells, but this had a negligible effect on the removal of non-viable 
cells. It is possible that reduced cell densities in the control cell line may be due to restricted 
cell growth during the period of time when the perfusion rate was ramped up. If the cells 
became growth restricted due to nutrient or metabolite limitations and entered apoptosis 
during this period of change in the perfusion rate, the cell density may never reach expected 
cell densities. Increasing the perfusion rate earlier in the culture period may lead to increased 
cell densities in the control cell line. Operating the perfusion cultures with a low cell bleed 
and analyzing the cells at steady state may be a better measure of the effect of bcl-2 on 
perfusion culture. 
Simpson et al. (1999) studied the effect of bcl-2 on cell cycle progression by growing 
cells in continuous chemostat cultures. They found that, at dilution rates between 0.6 and 0.8 
v/day (reactor volumes/day), there was slight difference in the viable cell density and 
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viability between the bcl-2 expressing cells and control cultures. If anything, it appears that 
the viable cell density may have been higher in the control cultures. As the dilution rate was 
decreased to 0.3 v/day, however the cell density and viability of the control culture dropped 
off quickly, while the bcl-2 expressors maintained a high cell density and viability. At a 
dilution rate of 0.2 v/day, the viable cell density and viabilities of both cultures dropped 
significantly. It was determined that the percentage of G1 cells in the bcl-2 culture was 80% 
compared to 56% in the control culture at a dilution rate of 0.2 v/day. These results suggest 
that bcl-2 affects the transition from the G1 to S phase, and this allows the cells to grow at 
suboptimal growth rates. This effect could be very important in growing cells at the low 
growth rates of high cell retention perfusion culture. 
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CHAPTER 2. BCL-2 EXPRESSION IMPROVES SURVIVAL OF A HYBRIDOMA 
CELL LINE IN BATCH CULTURE 
A paper prepared for submission to Biotechnology and Bioengineering 
Mark C. Mowry, Carole A. Heath, and Marit Nilsen-Hamilton 
ABSTRACT 
To determine the effect of BCL-2 content on hybridoma cell productivity, cells 
modified for bcl-2 expression were grown in batch culture in triplicate. Expression of bcl-2 
improved the viability of H166 hybridoma cells, but failed to improve antibody yield. 
BCL-2 began to increase the viable period of cell culture at levels as low as 2-5 units/cell, 
where one unit is defined as the amount of BCL-2 protein in a HL-60 cell taken at 48 h of 
batch culture. At a BCL-2 content of 10-27 units/cell, there was a further improvement in 
viability. At 27 units/cell, the culture maintained a viability of greater than 74% after 12 
days in batch culture compared to 33% for the vector-only control. It was determined that 
the increase in viability was due to a decrease in the percentage of cells entering apoptosis. 
Although the increase in viability led to an increase in viable cell density during the decline 
phase of batch culture, expression of bcl-2 did not have an effect on the specific or 
volumetric antibody productivities. The IgM concentration did not increase for the clones or 
the vector-only control after 7 days of culture. The clones with high BCL-2 content stop 
expressing IgM even though the cell membrane remained intact This result is different from 
that seen by previous investigators, who found that bcl-2 expression improved specific and 
volumetric antibody productivity. Bcl-2 expression did not affect the transition from the G1 
to the S phase of the cell cycle as has been suggested for other cell lines. In addition, bcl-2 
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expression had no effect on cell metabolism during batch culture as seen by analysis of 
glucose, glutamine, lactate and ammonia levels. 
INTRODUCTION 
Hybridoma cells have been developed for the large-scale production of monoclonal 
antibodies for use in applications, such as diagnostics assays, drug targeting and antigen 
purification (Kohler and Milstein, 1975). Attempts to increase antibody production resulted 
in culture conditions that optimize cell density, cell survival, and specific productivity. This 
has been accomplished by analyzing the effects on antibody production of various factors 
such as oxygen (Boraston et al., 1997), glutamine and glucose ratios (Law and Harbour, 
1985; Luan et al., 1987), amino acid supply (Duval et al., 1991), serum content (Heath et al., 
1990), ammonia and pH (McQueen and Bailey, 1989). In addition, cell cycle analysis 
showed that cells in G1 phase secreted monoclonal antibody at a faster rate than in other 
phases of the cell cycle (Al-Rubeai and Emery, 1990; Ramirez and Mutharasan, 1990). This 
information has been applied to optimizing conditions for growing cells in other reactor 
systems such as fed-batch and continuous cultures. 
A large portion of hybridoma cells die in batch culture as the result of a type of cell 
death known as apoptosis (Al-Rubeai et al., 1991; Franek and Vomastek, 1992; Mercille and 
Massie, 1994; Solis-Recendez et al., 1994). Apoptosis is a type of cell death in which cells 
actively participate and is the result of an intracellular program. It is characterized by 
condensation of the chromatin at the nuclear periphery and the eventual formation of 
apoptotic bodies. The apoptosis cascade may be set off by numerous environmental factors 
such as the buildup of toxic metabolites, oxygen limitation, withdrawal of growth factors, 
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heat shock, viral infection, nutrient limitation and low level shear stress (Thompson, 1995; 
Singh et al. 1996). By preventing hybridoma cells from undergoing apoptosis it may be 
possible to increase viable cell density and cell viability, and hence increase antibody yield. 
A number of genes have been identified that prevent apoptosis in a variety of cell 
lines. Among them, bcl-2 was identified in a study of B cell lymphomas by Tsujimoto et al. 
(1985) and was first shown to prolong cell survival in a study of IL-3 dependent B and 
myeloma cells (Vaux et al., 1988). Although the mechanism by which bcl-2 prevents 
apoptosis remains unclear, it has been suggested that bcl-2 located in the mitochondria may 
block the release of apoptogenic factors, such as cytochrome c and apoptosis inducing factor 
(AIF), that trigger the apoptotic response (Kluck et al., 1997; Yang et al., 1997; Tsujimoto 
and Shimizu, 2000). Bcl-2 and the other bcl-2 family members appear to regulate 
permeability of the inner and outer mitochondrial membranes through the permeability 
transition pore (PT) and the voltage-dependent ion channel (VDAC) (Harris and Thompson, 
2000; Tsujimoto and Shimizu, 2000). By regulating the release of apoptogenic factors, bcl-2 
is able to prevent the activation of caspases, a family of cysteine proteases that work together 
to carry out the apoptosis cascade (Green and Reed, 1998). In addition, bcl-2 may inhibit the 
apoptotic response by interacting with other bcl-2 family proteins with pro-apoptotic 
function. Bcl-2 counters the pro-apoptotic function ofbax by forming heterodimers with bax 
in vivo (Oltvai et al., 1993; Finnegan et al., 2001). Bag-1, another member of the bcl-2 
family of proteins increases the anti-apoptotic effect of bcl-2 (Takayama et al., 1995). 
Bcl-2 expression reduces the extent of apoptosis in a variety of cell types including 
myeloma, lymphoma, HeLa, HL-60, and MDCK cells (Vaux et al., 1988; Yin and Schimke, 
1995; Singh et al., 1996; Lee and Shacter, 1997; Lin et al., 1997; Yang et al., 1997). 
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Numerous studies have confirmed the anti-apoptotic effect of bcl-2 in hybridoma cells (Itoh 
et al., 1995; Simpson et al., 1998; Chung et al., 1998). Itoh et al. (1995) determined that 
overexpression of bcl-2 increased the maximum viable cell density by 45%, delayed the 
onset of apoptosis by 2 days and prolonged the viable culture period by 4 days in batch 
culture. Other investigators found similar results, although the extent to which bcl-2 
overexpression prevented apoptosis differed significantly. Overexpression of bcl-2 increased 
the viable period in hybridomas subjected to hypoxia, hyperoxia, glutamine deprivation, 
glucose deprivation, and serum depletion (Simpson et al., 1997). The protective effect of 
bcl-2 overexpression was more evident in low-serum and serum-free cultures (Chung et al., 
1998; Fassnacht et al., 1998). 
Numerous investigators have examined the effect of the level of bcl-2 expression on 
cell proliferation. Yin and Schimke (1995) developed a HeLa S3 cell line with inducible 
bcl-2 expression. They determined that protection from apoptosis increased with bcl-2 
expression in a hyperbolic manner. As the level of bcl-2 increased, so did the percentage of 
non-apoptotic cells. Itoh et al. (1995) made an attempt to examine hybridoma cells with 
different levels of bcl-2 expression. They did this by examining cells with bcl-2 driven by 
different promoters. The cytomegalovirus (CMV) promoter provided a high level of bcl-2 
expression, while bcl-2 expression driven by the mouse mammary tumor virus (MMTV) was 
undetectable by Western blotting. The cells expressing a high level of bcl-2 showed 
significant protection from apoptosis, while the low expressors appeared to provide no 
protection. 
The present study was conducted to determine the effect of various levels of bcl-2 
expression on hybridoma cell proliferation and the extent of apoptosis in batch culture. Here 
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we show that higher levels of bcl-2 overexpression resulted in an increase in the viable 
period of batch culture, although there was no increase in specific or volumetric antibody 
productivity. The specific antibody productivity during the growth period of batch culture 
remained unchanged, while productivity during the decline phase was minimal. The cells 
stop producing IgM even though the cell membrane remained intact We also show that 
lower levels of bcl-2 overexpression have little or no effect on hybridoma cell survival. 
Lastly, increased bcl-2 expression did not lead to any apparent changes in cell metabolism or 
cell cycle progression. 
MATERIALS AND METHODS 
Cell line maintenance 
A murine hybridoma cell line, H166, producing an IgM antibody, was obtained from 
Abbott Laboratories. The cells were cultured in Iscove's modified Dulbecco's medium 
(IMDM, Gibco BRL, Grand Island, NY), supplemented with 10% fetal bovine serum (FBS, 
Gibco BRL), 3.024 g/1 NaHCOs, and 103 units penicillin-streptomycin. The cells were 
grown in 250 ml Kontes spinner flasks (Fisher Scientific, Chicago, IL) at 37°C in humidified 
air containing 5% CO? Cells were stored as frozen aliquots at -140°C for later use. 
Vector construction 
The human bcl-2 fragment was obtained as an 821 bp fragment from plasmid 
pBcl2UHD (Yin and Schimke, 1995) by cutting with EcoKH blunting with klenow fragment 
and cutting again with HindUL This fragment was inserted into the multiple cloning site of 
pcDNA3.1 /Hygro(-) (Invitrogen, Carlsbad, CA) at the EcoKV and HindUl restriction sites. 
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The sequence and orientation of the corresponding construct was confirmed by sequencing 
the bcl-2 fragment and portions of pcDNA3.1 /Hygro(-) at the point of insertion. 
PcDNA3.1/Hygro(-) provides a selectable marker for hygromycin resistance, and 
transcription of bcl-2 mRNA is driven by a cytomegalovirus (CMV) promoter. 
Transfection of hybridoma celb with human bcl-2 gene 
The hybridoma cells were transacted with the DNA constructs by electroporation 
using a BTX electro cell manipulator (BTX, San Diego, CA). Cells were harvested from 75 
cm2 T-flasks two days after seeding at 2 x 105 viable cells/ml in hybridoma serum free media 
(HSFM, Gibco BRL). Cells were resuspended at 1 x 107 viable cells/ml in HSFM containing 
40 ng/ml of the pcDNAS. l/Hygro(-)/bcl-2 plasmid construct. Electroporation cuvettes 
(BTX) with a 2 mm gap were filled with 400 jj.1 of the cell suspension and stored on ice for 
10 min. The cells were then electroporated in the BTX 600 electro cell manipulator at 150-
200 V, 129 ohm, and 1200 pF. The cells were placed on ice for 10 min, and were then 
transferred to 12 well plates containing HSFM supplemented with 15% FBS. Stable 
transfectants were selected in the presence of hygromycin B (Gibco BRL) at 400 fig/ml and 
clones were obtained by limiting dilution. The vector-only control cell line was obtained by 
transfecting with 40 pg/ml of the pcDNA3. l/Hygro(-) plasmid. Stable transfectants were 
selected in the presence of hygromycin B and this population was used as a control cell line. 
After screening clones for BCL-2 content by Western blotting, cells were stored as frozen 
aliquots at -140 °C for later use. 
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Experimental conditions 
PcDNAS. l/Hygro(-)/bcl-2 clones with varying amounts of BCL-2 content as 
determined by Western blotting were selected in order to determine the effect of BCL-2 
content on cell proliferation. In addition, a vector-only control, that was obtained by 
transacting the H166 cells with pcDNA3. l/Hygro(-), was used as a negative control. The 
cells were taken from frozen stocks approximately two weeks prior to the experiments. Cells 
were grown in culture media consisting of IMDM containing 2.5% FBS, 3.024 g/L NaHCOs, 
103 units/1 penicillin-streptomycin, and 400 pg/ml hygromycin B. Cells from three different 
clones and the vector-only control were cultured in triplicate in 250 ml Kontes spinner flasks 
at 37°C in humidified air containing 5% CO2 for approximately 12 days. The cells were 
initially seeded into the spinner flasks at 2 x 105 viable cell/ml with viabilities of greater than 
85% in culture media lacking hygromycin B. Samples were taken from the spinner flasks 
daily for the analysis of culture conditions. 
Cell counts and apoptosis detection 
The viable cell density and the viability of cell populations were determined by 
counting cells stained with erythrosin B dye using a hemocytometer and a light microscope. 
Viability was calculated as number of viable cells/total cells in the population. The viable 
cell density was calculated as the total number of viable cells per ml of cell culture. The 
apoptotic index was determined by staining with acridine orange and ethidium bromide. 
Acridine orange and ethidium bromide were both added to cell suspensions at a final 
concentration of 5 pg/ml. Cells were placed on a hemocytometer and viewed under a 
fluorescence microscope. Normal/live cells contain bright green chromatin with an 
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organized structure, while early apoptotic cells have a bright green, highly condensed 
chromatin. Late apoptotic cells contain a bright orange, highly condensed chromatin, while 
necrotic cells simply have a bright orange chromatin. The concentration of cells was varied 
such that 20-50 cells were counted on each grid of the hemocytometer for both staining 
procedures. A total of at least ten randomly chosen grids were counted for each sample. 
Quantitative Western blotting 
Cell samples were washed in TBS (tris-buffered saline), lysed at 105 viable cells/pl in 
0.02 M HEPES buffer (pH 7.4) containing 0.5% NP40, 1% trasylol, and 1 mM phenyl 
methanesulfonyl fluoride (PMSF) at 0°C for 15 min, and stored at -70°C for later use. The 
lysates were boiled in sodium dodecyl sulfate (SDS) sample buffer for 2 min before being 
run on a 12.5% SDS-polyacrylamide gel. Lysates from 5 x 103 to 106 cells were loaded into 
each lane. Lysates from 5 x 104to 4 x 105 HL-60 cells taken 48 h after seeding in IMDM 
with 15% FBS were also loaded in order to quantitate BCL-2 content. Gels were transferred 
to nitrocellulose in a Hoe fer TE 50 transfer tank for 12 h at 30 V. Blots were blocked with 
5% nonfat dry milk containing 0.02% sodium azide for 1 h at room temperature. BCL-2 was 
detected by incubating with 1 pg/ml anti-BCL2 antibody (AB-1) (Oncogene, San Diego, CA) 
in 5% nonfat dry milk for 1.5 h followed by a 45 min incubation with 0.03 pg/ml HRP-
conjugated goat anti-mouse IgG antibody (Oncogene). The bands were detected by 
incubating with ECL (Amersham, Piscataway, NJ) and exposing to film. ECL is a light 
emitting non-radioactive method for detecting antigens conjugated to horseradish peroxidase-
labeled antibodies. The level of BCL-2 content was determined by measuring band intensity 
with a densitometer and comparing to that of HL-60 cell lysates. For quantitation purposes, 
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1 unit/cell of BCL-2 content is defined as the amount of BCL-2 protein in a HL-60 cell taken 
at 48 h of batch culture. The same HL-60 cell lysate preparation was used as a standard 
throughout these experiments. 
Analysis of BCL-2 content by flow cytometry 
Flow cytometry was also used to analyze the level of BCL-2 content. Samples were 
taken from batch culture, washed twice in PBS (phosphate-buffered saline), and stored on ice 
for 15 min. These samples were then fixed at 1 x 106 cells/ml in 70% ethanol and stored at 
-20°C for later analysis. Cells were washed twice in PBS, and incubated in the dark for 30 
min at 4°C in the presence of 10 pi FITC-conjugated anti-human BCL-2 antibody (Dako, 
Carpenteria, CA) per 106 cells. Cells were then washed and incubated in 200 pi of DNA 
staining medium containing 50 pg/ml propidium iodide and 100 Kunitz units/ml of RNase A 
(Sigma Diagnostics, St. Louis, MO). The cell suspension was stored in the dark for 30 min 
at 4°C. Cells were washed with PBS containing 2% FBS, and resuspended in 0.3 ml PBS. 
The cells were then analyzed at the Iowa State University Cell and Hybridoma Facility using 
a Coulter EPICS 752 flow cytometer. 
A similar procedure was used in preparing cells for cell cycle analysis by flow 
cytometry except that no antibody was added. Cell cycle distribution and bcl-2 expression 
were analyzed using WinMDI software provided by the FACS Core Facility website of the 
Scripps Research Institute. 
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Determination of antibody, substrate and metabolite concentrations 
The antibody concentration was determined by an enzyme linked immunosorbent 
assay (ELISA). Goat anti-mouse IgM polyclonal antibody (Roche, Indianapolis, IN) was 
bound overnight to 96 well Nunc immunoplates (Fisher Scientific) at a concentration of 5 
(ig/ml in a 0.1 M NaHCQ3 buffer (pH 9.6) at 4°C. Supernatant samples were diluted up to 
1/200 in PBS, 50 pi was added to each well and the plates were incubated overnight at 4°C. 
HRP-conjugated goat anti-mouse IgM polyclonal antibody (Roche) was then added at 0.33 
pg/ml for 4 hr at 37°C in PBS. 2, 2' -Azinobis(3-ethylbenzthiasoline sulfonic acid) (Roche) 
at a concentration of 1 mg/ml was then added to the plates and incubated at room temperature 
for 30 min. The absorbance at 405 nm of each sample was analyzed by an automated 
microplate reader (Bio-Tek Instruments, Winooski, VT). It should be noted that between 
each step the plates were washed twice with PBS containing 0.1% Tween 20, followed by 
washing twice with PBS alone. 
Glucose, glutamine, lactate and ammonia concentrations in the culture medium were 
measured using an Automated Microplate Reader (Bio-Tek Instruments) and enzymatic 
assay kits (Sigma Diagnostics). 
RESULTS AND DISCUSSION 
Effect of bcl-2 on cell density and viability 
H166 bcl-2 clones and the vector-only control were grown in batch culture in 
triplicate for approximately twelve days. The mean viable cell density, total cell density and 
viability obtained in batch culture for the different cultures are shown in Figures 1 and 2. 
The mean viable cell densities for each of the clones did not differ significantly from that of 
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Figure 1. Mean (A) viable and (B) total cell density of H166 clones grown in batch culture. 
The average inter-run standard deviation at each time point ranged from 2.1 — 4.9 x 10s 
cells/ml for each cell line tested. These large inter-run deviations led to viable and total cell 
densities that were not significantly different from the vector-only control according to a 
standard t test. 
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Figure 2. Mean viability of H166 clones grown in batch culture. The viability of each clone 
was not significantly different from the vector-only control according to standard t tests. 
This was due to a large average standard deviation of 4.7 - 9.3% for each cell line tested. 
the vector-only control, except for clone 2.8 at days 6 and 7, as determined by a standard t 
test. Clone 2.8 was the only clone to exhibit an increase in the maximum viable and total cell 
density during the culture period. The mean maximum viable cell density for clone 2.8 was 
2.5 x 106 cells/ml, while the maximum viable cell density of the control culture was 2.3 x 106 
cells/ml. The maximum viable cell densities of clones 1.1 and 4.2 were generally lower than 
that of the vector-only control. The mean viability at day 12 for clone 2.8 was 49%, while 
the viability of the control culture was 33%. The mean viability for clone 1.1 at day 12 was 
26%, while that for clone 4.2 was 22%. None of the mean viabilities or maximum cell 
densities was statistically different from that of the vector-only control as determined by at 
test. A large inter-run variation percentage led to a large standard deviation for each of the 
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viabilities and viable cell densities. These results initially suggested that bcl-2 expression did 
not lead to an improvement in viability or viable cell density for any of the clones, although 
individual runs did show some improvement. 
Determining the level of BCL-2 
To determine the actual effect of BCL-2, the amount of BCL-2 protein/cell was 
analyzed for each run. The level of BCL-2 content was determined by quantitative Western 
blotting (Figure 3) and by flow cytometry. The quantitative results of Western blotting 
showed that the mean level of BCL-2 was inconsistent for individual clones among runs 
(Figure 4). Clone 1.1 exhibited a consistently low level of BCL-2 of between 0.8 and 2 
units/cell during all three batch runs. The levels of BCL-2 in clones 2.8 and 4.2 were much 
more variable among the three runs. Clone 2.8 showed a maximum mean level of BCL-2 of 
27 units/cell, while clone 4.2 showed a maximum expression level of 10 units/cell. 
In addition to western blotting, the level of bcl-2 expression was monitored on a per 
cell basis by flow cytometry. This was done by labeling individual cells with a FITC 
conjugated anti-BCL-2 antibody. The labeling of clone 1.1, which exhibited a low amount of 
BCL-2 content by Western blot analysis, resulted in little increase in mean fluorescence or in 
the percentage of cells that exceeded the fluorescence generated by the control cell line 
(Figure 5). The low level of BCL-2 of this clone appears to be the result of a homogeneous 
population of cells that express at a low level. There was no evidence of an inhomogeneity 
with respect to BCL-2 content such as would have occurred if there were a secondary 
population of cells that expressed at a high level, while the majority of cells failed to express 
at all. Meanwhile, clones 2.8 and 4.2 exhibited mean fluorescence intensities that were up to 
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Figure 3. Western blotting of cell lysates from various bcl-2 expressing clones and a vector 
only control. HL-60 cell lysates from 10s to 4 xlO5 cells were loaded as positive controls for 
quantitation. The lysates from 5 x 104 viable cells are loaded for each of the HI 66 clones 
and the vector only control. Typically, various concentrations of the cell lysate are loaded in 
order to quantitate the level of expression. 
9 times that of the vector-only control. 
The mean percentage of clone 2.8 cells that exceeded the fluorescence intensity of the 
vector-only control was 96,48, and 88 for each of the three runs. These values are the 
average of several taken throughout each run. This result suggests that runs #1 and #3 
consisted of a single population of cells, while run #2 contained a secondary non-expressing 
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Figure 4. Level of BCL-2 as measured by quantitative Western blotting that was expressed 
by bcl-2 modified clones during each run. Figure 4A shows the mean level of BCL-2 
expression for each run and figure 4B shows a standard curve for BCL-2 quantitation. One 
unit of BCL-2 content is the amount of BCL-2 per HL-60 cell taken at 48 h of batch culture. 
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Figure 5. Analysis of bcl-2 expression by flow cytometry. Shows the mean percent of cells 
that exceed the fluorescence intensity of the vector-only control. 
population of cells. In addition, the percentage of clone 4.2 cells that exceeded the 
fluorescence intensity of the vector-only control were 97,95 and 96, respectively. This 
suggests that a majority of cells produced a significant amount of BCL-2 during each of the 
three runs. The effect of the level of BCL-2 content on hybridoma cell proliferation was 
determined by analyzing the runs for clones 2.8 and 4.2 individually. 
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Analysis of high expressing clones 
The reactor runs for clones 2.8 and 4.2, which express variable amounts of BCL-2 
must be analyzed separately to determine the true effect of BCL-2. The viable cell density 
and viability for each run are shown in Figures 6 and 7. The maximum viable cell densities 
for clones 2.8 and 4.2 were not a function of the level of BCL-2 content. Clone 2.8 exhibited 
the highest maximum viable cell density at a BCL-2 level of 27units/cell, but this 
concentration was not significantly different from that of the vector-only control. Clone 4.2 
exhibited the highest maximum viable cell density at an intermediate BCL-2 level of 3.8 
units/cell. This suggests that BCL-2 does not affect the maximum viable cell density of 
H166 hybridoma cells grown in batch culture as was observed for other hybridoma cell lines. 
BCL-2 did affect the viable cell density in H166 hybridoma cultures during the 
decline phase of batch culture. At a BCL-2 content of 27 units/cell, the viable cell density at 
day 12 was significantly higher than that of the vector-only control. The viable cell density 
of clone 2.8 at a BCL-2 level of 27 units/cell was 2.0 x 106 cells/ml, while that of the vector-
only control was only 9.1 x 105 cells/ml. At lower levels of BCL-2, the viable cell density at 
day 12 was not significantly different from that of the vector-only control. At a BCL-2 level 
of 2.5 units/cell the viable cell density was 7.8 x 105 cells/ml, while at 0.5 units/cell it was 
1.1 x 106 cells/ml. 
Clone 4.2, which produced variable amounts of BCL-2 for each run, behaved 
differently than the other clones or the vector-only control. The viable cell density and 
viability began to drop off abruptly after 7-8 days in culture due to a rapid pH drop. It was 
later determined that this pH drop was directly responsible for the rapid decline in cell 
density and viability (Data not shown). For this reason, all data for clone 4.2 taken after 8 
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Figure 6. The effect of bcl-2 on viable cell density during individual runs. A) Clone 2.8, B) 
Clone 4.2. 
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Figure 7. The effect of bcl-2 on viability during individual runs. A) Clone 2.8, B) Clone 4.2. 
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days in culture was ignored. After 7 days in culture, the viable cell density of clone 4.2 at a 
BCL-2 level of 10 units/cell was 1.6 x 10* cells/ml, while that of the vector-only control was 
1.7 x 106 viable cells/ml. At lower levels of BCL-2 content of 3.8 and 0.7 units/cell, the 
viable cell densities at day 7 were 1.9 x 106 and 9.5 x 105 cells/ml, respectively. These 
results show that high levels of BCL-2 can lead to an improvement in viable cell density 
during the decline phase of batch culture, although run and cell line variation may be more 
important. 
The viability of clone 2.8 at a BCL-2 level of 27 units/cell was 77% compared to 33% 
for the vector-only control at 12 days in batch culture. At a BCL-2 level of 2.5 units/cell the 
viability at day 12 was 40%, while at a BCL-2 level of 0.5 units/cell it was 30%. The 
viability of clone 4.2 at a BCL-2 content of 10 units/cell was 89% compared to 66% for the 
vector-only control at 7 days in batch culture. At a BCL-2 level of 3.8 units/cell the viability 
at day 7 was 79%, while at a BCL-2 level of 0.7 units/cell it was 67%. Both clone 2.8 at day 
12 of batch culture and clone 4.2 at day 7 showed an increase in viability with BCL-2 
content In addition, the clones with higher BCL-2 contents had significantly higher 
viabilities than the vector-only control. These results show that BCL-2 begins to protect 
H166 hybridoma cells from cell death at an expression level of 2-5 units/cell, with increasing 
protection at higher levels of BCL-2. 
To further analyze the effect of BCL-2 on cell proliferation, the viable cell density 
and viability were examined as a function of BCL-2 content (Figure 8). The viable cell 
density of the vector-only control ranged between 1.3 and 2.2 x 106 cells/ml at day 7 of batch 
culture. The viable cell density of the clones was primarily in this range and showed no trend 
with BCL-2 content The viability of the clones at day 7 increased significantly with BCL-2 
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Figure 8. Analysis of the effect of BCL-2 content during individual runs. A) Viable cell 
density, B) Viability. 
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content The viability clone 4.2 at a BCL-2 level of 3.8 units/cell was 79% compared to a 
mean viability of 66% for the vector-only control. At the level of BCL-2 content was 
increased above 10 units/cell, the viability increased to greater than 85%. These results 
confirm that bcl-2 expression leads to an increase in viability at levels as low as 2-5 
units/cell. 
In addition, the effect of BCL-2 content of specific cell death rate and the rate of loss 
of viability were also analyzed (Figure 9). The specific cell death rate decreased by a factor 
of greater than 2 at BCL-2 levels above 10 units/cell. This decrease in the specific cell death 
rate first became apparent at BCL-2 levels of 2-5 units/cell. These results were confirmed by 
analyzing the rate of viability decline in these cultures. The viability of the vector-only 
control declined at a rate of about 8% per day, while the viability in cultures with greater than 
10 units/cell of BCL-2 declined at 3-4% per day. This decrease in the loss of viability also 
became apparent at BCL-2 levels of 2-5 units/cell. These results confirm that bcl-2 
overexpression leads to an increase in viability during the decline period of batch culture at 
elevated levels of BCL-2 content. This increase in viability allows these cultures to maintain 
higher viable cell densities. 
Effect of bcl-2 on the extent of apoptosis 
To determine whether the decrease in the rate of cell death during the decline portion 
of cell culture was due to a decrease in apoptosis, the percent of cells undergoing apoptosis 
was determined by staining with acridine orange and propidium iodide and examining cell 
morphology. H166 hybridoma cultures expressing higher levels of BCL-2 showed decreased 
apoptosis. For example, clone 2.8 at a BCL-2 level of 27 units/cell, showed a significant 
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Figure 9. Analysis of the effect of BCL-2 content during individual runs. A) Specific cell 
death rate, B) Rate of viability decline. 
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delay in the onset of apoptosis in large numbers. In the vector-only control cells the 
percentage of viable/apoptotic cells exceeded 5% on day 6 and reached levels as high as 9%. 
For clone 2.8 (27 units/cell) the percentage of viable/apoptotic cells remained below 3% 
throughout the culture period (Figure 10). At lower levels of BCL-2 of 0.5 and 2.5 units/cell, 
there was not a significant decrease in the extent of apoptosis for clone 2.8. The same effect 
can be seen in the growth of clone 4.2. There was a distinct decrease in the frequency of 
apoptosis in the second and third runs that expressed bcl-2 at a level of 3.8 and 10 units, 
respectively. At a BCL-2 level of 3.8 units/cell, the percentage of viable/apoptotic cells did 
not exceed 4%, while at 10 units/cell it did not exceed 3% throughout the culture period. 
This decrease in apoptosis resulted in improved viabilities during the decline period of batch 
culture at BCL-2 contents greater than 2-5 units/cell. 
The effect of bcl-2 expression on apoptosis was further analyzed by comparing the 
percentage of apoptotic cells at day 10 of batch culture to the level of BCL-2 (Figure 11). At 
low levels of BCL-2, approximately 10% of the cells were found to be viable/apoptotic, 
while at levels above 10 units/cell less than 2% of the cells were found to be viable/ 
apoptotic. Similar to the results for viability, this decrease in the extent of apoptosis first 
becomes apparent at BCL-2 levels of 2-5 units/cells. 
Effect of bcl-2 on cell metabolism and antibody productivity 
To determine the effect of bcl-2 on hybridoma cell metabolism and antibody 
productivity the IgM, glucose, glutamine, ammonia and lactate concentrations in the medium 
were monitored throughout the culture period. The antibody production of clone 2.8 was 
significantly higher than that of the vector-only control or the rest of the clones (Figure 12). 
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Figure 10. Bcl-2 has an anti-apoptotic effect of H166 hybridoma cells at high levels of 
expression. (A) Clone 2.8, (B) Clone 4.2. 
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Figure 11. The effect of BCL-2 content on viable/apoptotic cell fraction during individual 
runs. 
Because clone 2.8 had a high BCL-2 content during some of the runs, this result suggests that 
bcl-2 expression, either directly or indirectly, may have resulted in an increase in IgM 
productivity. Looking at the three runs for clone 2.8 individually, it can be seen that there is 
no significant difference in IgM concentration among each of the three runs (Figure 13). 
Clone 1.1, which consistently had a low BCL-2 content, resulted in antibody concentrations 
that did not differ significantly from that of the vector-only control. The antibody production 
of Clone 4.2, which had variable BCL-2 content, also did not differ significantly from that of 
the vector-only control. In addition the specific rate of IgM production during any of the 
individual runs was not significantly different from that of the vector-only control (Table 1 ). 
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Figure 13. The effect of BCL-2 content on specific IgM productivity during individual runs. 
These results show that any variations in IgM production were due to differences between 
clones and not a direct consequence of bcl-2 expression. In all of the clones tested, the IgM 
concentration leveled off after 7-8 days of batch culture, regardless of the level of BCL-2 
content (Figures 12 and 13). Even though bcl-2 expression led to higher viabilities, it did not 
lead to an increase in IgM production. For this reason, modifying H166 hybridomas for 
bcl-2 overexpression did not lead to improved antibody yields. 
In addition to the antibody concentration, the glucose, glutamine, lactate, and 
ammonia concentrations of the culture media were determined. There were no apparent 
differences in the glucose, glutamine, lactate or ammonia concentrations in the media of the 
bcl-2 clones from that of the vector-only control, except for that of clone 4.2. Clone 4.2 
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Table 1. Average specific rates of production and consumption during the growth period of 
batch culture. 
Run Bcl-2 IgM Glucose Glutamine Lactate Ammonia 
(units/cell) (mg/cell/d) (mg/cell/d) (mg/cell/d) (mg/cell/d) (mg/cell/d) 
Vector-only (1) 0 9.4 x 10"9 5.2 x IO-5 2.3 x IO"? 5.9 x 10-6 1.1 x IO"8 
Vector-only (2) 0 3.0 x to'* 5.5 x 10"6 1.8 x IO'7 5.9 x 10-6 8.0 x IO'9 
Vector-only (3) 0 4.5 x 10 9 6.3 x IO"6 1.5 x IO*7 8.0 x 10-6 1.1 x IO-8 
Clone 1.1 (1) 0.9 5.6 x IO"9 4.5 x 10"6 2.3 x lO 7 6.8 x 10-6 8.4 x IO'9 
Clone 1.1 (2) 1.2 4.3 x 10 9 6.5 x IO"6 2.3 x I0'7 5.4 x 10-6 9.5 x IO'9 
Clone 1.1 (3) 1.6 3.8 x 10 9 7.4 x 10"6 1.6 x IO*7 5.4 x 10-6 8.3 x 10 9 
Clone 2.8(1) 0.5 6.6 x ÎO 9 1.9 x 10"6 1.7 x IO'7 3.1 x I0-6 1.4 x IO"8 
Clone 2.8 (2) 2.5 1.1 x IO"8 8.4 x IO"5 2.3 x 10 7 12 x IO-6 5.4 x lO9 
Clone 2.8 (3) 27 9.2 x 10 9 9.1 x 10"6 2.2 x 10 7 5.8 x IO"6 7.8 x 10 9 
Clone 42(1) 0.7 7.0 x 10 9 7.8 x 10"6 1.7 x IO'7 7.3 x IO-6 2.6 x 10 8 
Clone 4.2 (2) 3.8 2.8 x lO 9 6.1 x 10-6 2.2 x 10 7 7.5 x IO"6 8.7 x IO'9 
Clone 4.2 (3) 10 4.4 x 10 9 1.0 x 10-6 2.2 x IO'7 7.3 x IO-6 1.1 x IO-8 
exhibited lower glucose concentrations and higher lactate and ammonia concentrations 
compared to that of the vector-only control. These results correspond with the observation 
that the pH of this culture often dropped to 6.5, while the rest of the cultures remained above 
6.9. Analysis of supernatant samples during the growth period of batch culture showed that 
there was not a significant difference in the consumption and production rates as direct result 
of bcl-2 expression (Table I). It appears from these findings that bcl-2 overexpression does 
not alter the metabolism of H166 hybridoma cells. 
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Cell cycle analysis 
Previous investigators have suggested that bcl-2 prevents apoptosis by preventing 
cells from entering the S phase of the cell cycle (Simpson et al., 1999). To determine if this 
was the case for the H166 cells used in this study, a cell cycle analysis was performed to 
determine whether cells transacted with bcl-2 spend a larger amount of time in GO/GI phase. 
Samples taken from the run #3 of clone 2.8, which expressed the highest amount of bcl-2, 
were examined by flow cytometry, and compared to the vector-only control samples taken 
from the same run. There was little difference in the percentage of cells in Gq/Gi between 
bcl-2 expressing cells and the vector-only control over the course of the culture (Figure 14). 
The only significant difference between the results of the two cultures was at day 1 where the 
control cell line had a more rapid transition into S phase after seeding in fresh media. These 
results are different from those of Simpson et al. (1999), who found that a larger proportion 
of bcl-2 transfected TB/C3 hybridoma cells were in G1 phase during continuous culture 
compared to the vector-only control. These results show that restriction of the cells to G1 
phase is not necessary for prevention of apoptosis in all cell lines. 
CONCLUSIONS 
Overexpression of bcl-2 resulted in an increase in the viability and viable cell density 
of H166 hybridoma cells during the decline period of batch culture. This improved viability 
was apparent at levels of BCL-2 as low as 2-5 units/cell, with one unit/cell being defined as 
the amount of BCL-2 per HL-60 cell taken at 48 h of batch culture. At this level of 
expression the effect on viability is minimal, with an increase of less than 10% at all points 
during the decline portion of cell culture. At higher levels of BCL-2 content of 10 and 27 
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Figure 12. Analysis of the effect of BCL-2 on H166 hybridoma cell cycle progression. This 
plot compares the percnetage of vector-only control cells and clone 2.8 cells (27 units BCL-2 
content/cell) in various phases of the cell cycle. High BCL-2 content does not affect the cell 
cycle progression of H166 hybridoma cells. 
units/cell, there was a further improvement in viability and viable cell density. The viability 
for clone 2.8 (27 units/cell) remained above 74% during the entire culture period, which was 
significantly higher than the 33% seen in the vector-only control. 
In addition, bcl-2 expression led to a decrease in the rate at which viable cell density 
and viability declined. At BCL-2 contents greater than 10 units/cell, the rate of decline of 
viable cell density was less than half that of the vector-only control. Analysis showed that 
the reason for this decline was due to a decrease in the extent of apoptosis. The percentage 
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of viable apoptotic cells was less than 4% at all times during batch culture at BCL-2 contents 
greater than 3 units/cell, compared to 9% for the vector-only control. 
One of the most significant findings was that bcl-2 overexpression did not lead to an 
increase in the specific or volumetric antibody productivity of the H166 hybridomas. In fact, 
the IgM content did not increase after 7 days of batch culture. This result suggests that 
modifying H166 hybridoma cells for bcl-2 is not a viable method for improving antibody 
yield, although this approach has proved successful in other hybridoma cell lines (Itoh et al., 
1995; Simpson et al., 1997). Bcl-2 overexpression caused no effect on the glucose, 
glutamine, lactate or ammonia concentrations during any period of batch culture. In addition, 
a cell cycle analysis by flow cytometry revealed no change in the percentage of cells in G1 
phase. This shows that preventing cells from entering S phase is not necessary for the anti-
apoptotic effect of bcl-2. 
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CHAPTER 3. BCL-2 DOES NOT IMPROVE PRODUCTIVITY IN LONG-TERM 
PERFUSION CULTURE 
A paper prepared for submission to Biotechnology and Bioengineering 
Mark C. Mowry, Carole A. Heath, and Marit Nilsen-Hamilton 
ABSTRACT 
Bcl-2 was overexpressed in H166 hybridoma cells to prevent apoptosis, and, as a 
consequence, to increase viable cell density, viability and possibly antibody productivity in 
long-term perfusion culture. At a cell bleed rate of 0.75 v/d (reactor volumes/day), where the 
extent of apoptosis was expected to be low, bcl-2 did not improve the viable cell density or 
viability. Clone 2.8 had some improvement in cell density, but this was not consistent with 
the other clones tested. At lower cell bleed rates (0.25 and 0.1 v/d), where apoptosis was 
more likely to affect cell density, bcl-2 had a negative effect on the viable cell density and 
little effect on the viability. At the lowest cell bleed rate (0.1 v/d), the vector-only control 
reached a viable cell density of 2.2 x 107 cells/ml, while the cells modified for bcl-2 
expression reached viable cell densities of 1.2 — 1.5 x 107 cells/ml. The viability of the 
cultures showed no trend with BCL-2 content. The viability of the vector-only control 
declined to 76%, while the cells modified for bcl-2 expression declined to viabilities of 69 -
81%. The percentage of viable/apoptotic cells remained low throughout all the perfusion 
runs, which may have been a consequence of the short period of time that it takes for cells to 
undergo apoptosis. It is also possible that the extent of apoptosis remained low because cell 
death occurred by other factors, presumably necrosis. Regardless, bcl-2 did not reduce the 
percentage of viable/apoptotic cells in these cultures. In addition, antibody expression was 
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highly variable among all of the runs, but did not correlate with bcl-2 expression. Bcl-2 
expression also had no effect on cell metabolism or cell cycle progression. 
INTRODUCTION 
Perfusion reactors have been studied for use in large-scale production of monoclonal 
antibodies. Perfusion systems provide the advantages of increased yield on medium use, 
easy monitoring and control of culture conditions and ease of scale up. In addition, 
volumetric productivities of 40 times that seen in batch culture and 20 times that of semi-
continuous culture can be achieved (Reuveny et al., 1986), which result from increased cell 
densities and, in some cases, increased specific antibody productivities by cells in perfusion 
cultures (Ramirez and Mutharasan, 1990; Suzuki and Ollis, 1990; Banik and Heath, 1995). 
Attempts to optimize cell densities in perfusion systems have resulted in reported cell 
densities as high as 2 x 107 viable cells/ml (Reuveny et al., 1986; Banik and Heath, 1995). 
Viable cell density fails to increase further even in the apparent absence of nutrient or waste 
inhibition (Banik and Heath, 1995). De la Broise et al. (1991) determined that hybridomas 
grown in perfusion culture represent a "grow or die" system. This suggests that if the bleed 
rate is reduced to the point at which the cells are not permitted to grow, they will begin to 
die. Lowering the cell bleed rate should result in an increase in the viable cell density up 
until a point and then dead cells begin to build up in the system and may cause the reactor to 
"crash" at extremely low cell bleed rates. 
Cell death at these low cell bleed rates occurs presumably as the result of apoptosis, 
which is a type of cell death that results from an internal cellular program. Studies have 
shown that apoptosis accounts for a large percentage of cell death in batch culture (Mercille 
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and Massie, 1994b; Singh et al., 1994). Apoptosis can be caused by many factors including 
nutrient limitation (Singh et al., 1994; Mercille and Massie, 1994a), oxygen limitation 
(Mercille and Massie, 1994b), high temperatures (Nagarathnamma et al., 1997), and shear 
stress (Al-Rubeai et al., 1995). These factors can lead to cell death via apoptosis in perfusion 
culture and presumably lead to a decrease in viable cell density and viability. 
Apoptosis in hybridoma cells and numerous other cell types can be reduced to 
varying degrees by over-expressing the oncogene bcl-2 at high levels (Vaux et al., 1988; Itoh 
et al., 1995; Simpson et al. 1997, Chung et al., 1997). The extent of protection from 
apoptosis appears to depend on various factors including cell type and culture conditions. 
Bcl-2 appears to prevent cell death by altering the permeability of the mitochondrial 
membrane to cytochrome c, apoptosis inducing factor, and other apoptogenic factors (Kluck 
et al., 1997; Yang et al., 1997, Tsujimoto et al., 2000). By blocking the release of 
apoptogenic factors, bcl-2 prevents the activation of various caspases that cause protein 
degradation and lead directly to the apoptosis cascade (Green and Reed, 1998). 
The effect of bcl-2 on hybridoma cell proliferation has been examined in numerous 
studies. For example, Simpson et al. (1999) determined that there was little difference 
between bcl-2 expressing cultures and control cultures in CSTR (continuous stirred tank 
reactor) at high dilution rates, but at lower dilution rates bcl-2 led to a significant increase in 
both viable cell density and viability. These conditions are different from that seen in 
perfusion culture in that cells may die as the result of nutrient depletion and metabolite 
inhibition. It does suggest however that it may be possible to increase viable cell density in 
perfusion culture by growing cells that overexpress bcl-2. 
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Bierau et al. (1998) determined that bcl-2 expression led to an increase in both the 
viable cell density and the viability, but did not affect volumetric antibody productivity in 
perfusion culture with total cell retention. The conditions obtained in total cell retention 
perfusion culture are similar to batch culture in that cells are not removed from the 
bioreactor, however in perfusion culture the media is continually replaced. Steady state can 
not be achieved at total cell retention, and therefore, viable cell density and viability began to 
decline in both bcl-2 modified and control cell lines. 
Initial studies in our lab have shown that H166 hybridoma cells grown at nearly total 
cell retention die predominantly by apoptosis. This suggests that it may be possible to 
decrease the rate of cell death in homogeneous perfusion systems by preventing cell death 
resulting from apoptosis. This decrease in the rate of cell death by apoptosis may allow for 
operation of homogeneous perfusion reactors at low cell bleed rates without a dramatic 
decrease in the viability. The hypothesis is that operation at a lower cell bleed rate will lead 
to an increase in the steady state viable cell density and a corresponding increase in IgM 
production. Batch studies on the H166 cell line used in this study demonstrated a decrease in 
the rate of cell death at increased levels of bcl-2 expression (Mowry et al., 2001). Here we 
explore the possibility that this decrease in the rate of cell death by preventing or reducing 
apoptosis may lead to an increase in productivity in long term perfusion culture at low cell 
bleed rates. 
In the current study, cells modified for bcl-2 expression and a vector-only control 
were grown at three different cell bleed rates to determine the effect of bcl-2 expression on 
hybridoma cell proliferation in perfusion culture. It was reasoned that, if bcl-2 expression 
inhibits cell death by apoptosis, then the viable cell density and antibody yield would 
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increase accordingly. This improvement in viability may allow for the reactor to be operated 
with a very low cell bleed, resulting in even greater cell densities without reducing viability. 
Various clones were studied in order to determine if there is an optimal level of bcl-2 
expression for productivity, and to ensure that any observed change is not specific to a single 
population of cells. 
MATERIALS AND METHODS 
Cell line maintenance 
A murine hybridoma cell line, H166, producing an IgM antibody, was obtained from 
Abbott Laboratories. The cells were cultured in Iscove's modified Dulbecco's medium 
(IMDM, Gibco BRL, Grand Island, NY), supplemented with 10% fetal bovine serum (FBS, 
Gibco BRL), 3.024 g/1 NaHCOs, and 105 units penicillin-streptomycin. The cells were 
grown in 250 ml Kontes spinner flasks (Fisher Scientific, Chicago, IL) at 37°C in humidified 
air containing 5% CCK Cells were stored as frozen aliquots at -140°C for later use in 
experiments. 
Vector construction 
The human bcl-2 fragment was obtained as an 821 bp fragment from plasmid 
pBcl2UHD (Yin and Schimke, 1995) by cutting with JEcoRI, filling in with Klenow fragment 
and cutting again with HindHL This fragment was inserted into the multiple cloning site of 
pcDNAS. l/Hygro(-) (Invitrogen, Carlsbad, CA) at the £coRV and Hindill restriction sites. 
The sequence and orientation of the corresponding construct was confirmed by sequencing 
the bcl-2 fragment and portions of pcDN A3. 1 /Hygro(-) at the points of insertion. 
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pcDN A3.1 /Hygro(-) provides a selectable marker for hygromycin resistance, and 
transcription of bcl-2 mRNA is driven by a cytomegalovirus (CMV) promoter. 
Transfection of hybridoma cells with human bcl-2 gene 
The hybridoma cells were transacted with the DNA constructs by electroporation 
using a BTX electro cell manipulator (BTX, San Diego, CA). Cells were harvested from 75 
cm2 T-flasks two days after seeding at 2 x 105 viable cells/ml in hybridoma serum free media 
(HSFM, Gibco BRL). Cells were resuspended at 1 x 107 viable cells/ml in HSFM containing 
40 pg/ml of the pcDNA3. l/Hygro(-)/bcl-2 plasmid construct Electroporation cuvettes 
(BTX) with a 2 mm gap were filled with 400 pi of the cell suspension and stored on ice for 
10 min. The cells were then electroporated in the BTX 600 electro cell manipulator at 150-
200 V, 129 ohm (setting R5), and 1200 jaF. The cells were placed on ice for 10 min, and 
were then transferred to 12-well plates containing HSFM supplemented with 15% FBS. 
Stable transfectants were selected in the presence of hygromycin B (Gibco BRL) at 400 
Hg/ml and clones were obtained by limiting dilution. The vector-only control cell line was 
obtained by transacting with 40 pg/ml of the pcDN A3.1 /Hygro(-) plasmid. Stable 
transfectants were selected in the presence of hygromycin B and this population was used as 
a control cell line. After screening clones for bcl-2 expression by Western blotting, cells 
were stored as frozen aliquots at -140 °C for later use. 
Design and operation of the perfusion system 
The perfusion reactor consists of a jacketed glass vessel with working volumes of 650 
ml. The temperature was maintained at 37 °C by pumping water through the glass jacket. 
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The dissolved oxygen concentration was maintained between 40 and 50% by varying the air 
to oxygen ratio flowing into the reactor through a microporous sparger. Reactors were well 
mixed with a magnetic stirrer at 70-80 rpm. The reactor pH was controlled between 7.0 and 
7.1 by supplying 5% CO2, along with the air, and by adding from a stock solution of 0.5 M 
NaHCO] as needed. The pH and dissolved oxygen were both monitored by an Applikon 
control system. The reactors were initially inoculated with cells (2-3 x 105 cells/ml) from an 
exponentially growing batch culture and were run in batch mode until the density increased 
to more than 106 cells/ml, after which cell-free bleeding was initiated. Reactors could be 
operated in either CSTR or perfusion mode. The liquid level was maintained at 650 +/- 10 
ml with a chemostat tube. During perfusion operation, medium was removed from the 
reactors in two ways. The permeate stream consisted of a cell-free bleed removed through a 
hollow fiber membrane cartridge, while the other stream was removed directly from the 
reactor, determining the cell bleed rate. Masterflex peristaltic pumps (Cole-Parmer, Vernon 
Hills, IL) were used for medium feed and removal, as well as for recirculation through an 
external loop. The external loop contains a hollow fiber membrane cartridge (A/G 
Technology Corporation, Needham, MA) (50 polysulfone hollow fibers with a 0.45 pm pore 
size, 0.032 m2 membrane area, 1 mm lumen ID, 6 ml hold up volume) that was used to 
remove a cell-free bleed from the reactors. 
Cell counts and apoptosis detection 
The viable cell density and viability of samples were determined by staining with 
erythrosin B dye and counting the cells on a hemocytometer using light microscopy. 
Detection of cell viability and the extent of apoptosis were determined by staining with 
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acridine orange and ethidium bromide. Both acridine orange and ethidium bromide were 
added to a cell suspension to a final concentration of 5 pg/ml. Cells were then placed on a 
hemocytometer and viewed under a fluorescence microscope. Nuclei in normal/live cells 
stain bright green with an organized chromatin structure, while early apoptotic cells stain 
bright green with highly condensed chromatin. Nuclei of late apoptotic cells stain bright 
orange with highly condensed chromatin, while nuclei of necrotic cells stain bright orange. It 
can be difficult to distinguish late apoptotic from necrotic cells. The concentration of the 
cells was varied such that 20-50 cells were counted on each grid of the hemocytometer for 
both staining procedures. A total of at least ten grids were counted for each sample. 
Quantitative Western blotting 
Cell samples were washed in TBS (Tris-buffered saline), lysed at 105 viable cells/|il 
in 0.02 M HEPES buffer (pH 7.4) containing 0.5% NP40, 1% trasylol, and 1 mM phenyl 
methanesulfonyl fluoride (PMSF) at 0°C for 15 min, and stored at -70°C for later use. The 
lysates were boiled in sodium dodecyl sulfate (SDS) sample buffer for 2 min before being 
run on a 12.5% SDS-polyacrylamide gel. Lysates from 5 x 103 to 106 cells were loaded into 
each lane. Lysates from 5 x 104to 4 x 105 HL-60 cells taken 48 h after seeding in IMDM 
with 15% FBS were also loaded to provide a standard curve by which to quantitate the 
concentration of BCL-2 in the cells. After electrophoresis, gels were transferred to 
nitrocellulose in a Hoefer TE 50 transfer tank for 12 h at 30 V. The blots were incubated 
with 5% nonfat dry milk containing 0.02% sodium azide for 1 h at room temperature. BCL-2 
was detected by incubating with 1 ng/ml anti-BCL2 antibody (AB-1) (Oncogene, San Diego, 
CA) in 5% nonfat dry milk for 1.5 h followed by a 45 min incubation with 0.03 pg/ml HRP-
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conjugated goat anti-mouse IgG antibody (Oncogene). The bands were detected by 
incubating with ECL (Amersham, Piscataway, NJ) and exposing to film. ECL is a light 
emitting non-radioactive method for detecting antigens conjugated to horseradish peroxidase-
labelled antibodies. The level of BCL-2 content was determined by measuring band intensity 
with a densitometer and comparing to that of HL-60 cell lysates. For quantitation purposes, 
1 unit/cell of BCL-2 content is defined as the amount of BCL-2 protein in a HL-60 cell taken 
at 48 h of batch culture. The same HL-60 cell lysate preparation was used as a standard 
throughout these experiments. 
Preparation of cells for flow cytometry 
In addition to Western blotting, flow cytometry was used to determine the amount of 
BCL-2 on a per cell basis. Samples were taken from batch culture, washed twice in PBS 
(Phosphate-buffered saline), and stored on ice for 15 min. These samples were then fixed at 
a density of 1 x 106 cells/ml in 70% ethanol and stored at -20°C prior to analysis. Cells were 
washed twice in PBS, and incubated in the dark for 30 min at 4°C in the presence of 10 #il 
FITC-conjugated anti-human bcl-2 antibody (Dako, Carpenteria, CA) per 106 cells. Cells 
were then washed and incubated in 200 pi of DNA staining medium containing 50 pg/ml 
propidium iodide and 100 Kunitz units/ml of RNase A (Sigma Diagnostics, St. Louis, MO). 
The cell suspension was stored in the dark for 30 min at 4°C. Cells were washed with PBS 
containing 2% FBS, and resuspended in 0.3 ml PBS. The cells were then analyzed at the 
Iowa State University Cell and Hybridoma Facility using a Coulter EPICS 752 flow 
cytometer. 
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A similar procedure was used to prepare cells for cell cycle analysis by flow 
cytometry except that no antibody was added. Cell cycle distribution and bcl-2 expression 
were analyzed using WinMDI software provided by the F ACS Core Facility website of the 
Scripps Research Institute. 
Determination of antibody, substrate, and metabolite concentrations 
The antibody concentration was determined by an enzyme linked immunosorbent 
assay (ELISA). Goat anti-mouse IgM polyclonal antibody (Roche, Indianapolis, IN) was 
bound overnight to 96 well Nunc immunoplates (Fisher Scientific) at a dilution of 1/200 in a 
0.1 M NaHCOa buffer (pH 9.6) at 4°C. Supernatant samples were diluted up to 1/200 in 
PBS, 50 ml was added to each well and the plates were incubated overnight at 4°C. HRP-
conjugated goat anti-mouse IgM polyclonal antibody (Roche) was then added at a 1/3000 
dilution for 4 h at 37°C in PBS. 2,2' -Azinobis(3-ethylbenzthiazoline sulfonic acid) (Roche) 
at a concentration of 1 mg/ml was added to the plates, which were then incubated at room 
temperature for 30 min. The absorbance at 405 run of each sample was analyzed by an 
automated microplate reader (Bio-Tek Instruments, Winooski, VT). It should be noted that, 
between each step, the plates were washed twice with PBS containing 0.1% Tween 20, 
followed by washing twice with PBS alone. Glucose, glutamine, lactate and ammonia 
concentrations were measured using enzymatic assay kits (Sigma Diagnostics) whose outputs 
were measured by an automated microplate reader (Bio-Tek Instruments). 
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RESULTS AND DISCUSSION 
Effect of bcl-2 on viable cell density, viability and extent of apoptosis 
Three H166 hybridoma clones that produced different amounts of BCL-2 and a 
vector-only control were grown to determine the effect of BCL-2 on cell density and 
antibody productivity in long-term perfusion culture. These cells were initially seeded at 2 x 
10s viable cells/ml and were allowed to grow in batch culture for 3-5 days, when the viable 
cell density reached 106 viable cells/ml. The dilution rate was then slowly increased to 2 v/d. 
The cells were initially grown without a cell bleed to achieve steady state as quickly as 
possible. When the viability of the reactors began to drop, a cell bleed was taken and the 
reactors were allowed to reach steady state. The hybridomas were grown at cell bleed rates of 
0.1, 0.25 and 0.75 v/d. 
The cells were grown in perfusion culture by slowly increasing the dilution and cell 
bleed rates to 2.0 and 0.75 volumes/day, respectively. These flowrates were chosen as 
controls because at this growth or dilution rate the extent of apoptosis would be low, and 
therefore, the cultures were unlikely to benefit from the expression of bcl-2. Simpson et. al. 
(1999) determined in continuous chemostat cultures of hybidoma cells that bcl-2 had no 
effect on the viability or viable cell density at dilution rates above 0.6 v/d. The vector-only 
control was grown in triplicate in order to show that the cells reach the same steady state 
conditions regardless of the starting conditions for the reactor run. For the three repeated runs 
of the vector-only control, the steady state viable cell density was 2.9 ± 0.35 x 106 viable 
cells/ml and the viability was 90 ± 2.4%, at a dilution rate of 2.0 v/d and a cell bleed rate of 
0.75 v/d. This shows that the steady-state conditions are approximately the same regardless 
of run variation (Figure 1). 
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At a cell bleed rate of 0.75 v/d, the steady state viable cell density for clones 1.1, 2.8 
and 4.2 were 2.4 x 106, 5.5 x 106 and 2.8 x 106 cells/ml. The steady state viabilities for the 
three clones were 89, 92, and 86%, respectively (Table 1), which were not significantly 
different from that of the vector-only control. The average viability of the three bcl-2 
expressing clones was 89.1 ± 2.8%, which is very similar to the results obtained for the 
vector-only control. The steady state viable cell density was highly variable for the three 
clones modified for bcl-2 expression (Table 1). Clone 1.1 and clone 4.2 had slightly lower 
steady state viable cell densities than the vector-only control, but were not statistically 
different. Clone 2.8 had a steady state viable cell density of 5.5 x 106 cells/ml, which was 
significantly different from that of the vector-only control. The average steady state viable 
cell density for the three clones was 3.6 ± 1.7 x 106 cell/ml. These results suggest that bcl-2 
may increase the steady state viable cell density of H166 cells grown in perfusion culture at a 
cell bleed rate of 0.75 v/d. 
At lower cell bleed rates (0.25 and 0.1 v/d), it was expected that higher intracellular 
levels of BCL-2 would lead to an increase in the viable cell density and the viability in 
comparison to the vector-only control. The steady state viability for the vector-only control 
was 86 % at a cell bleed rate of 0.25 v/d and 76% at 0.1 v/d. The three clones tested had an 
average steady state viability of 78.9 ± 2.4% at a cell bleed rate of 0.25 v/d, and 73.7 ± 6.1% 
at 0.1 v/d (Figure 2). The steady-state viable cell densities for the vector-only control were 
1.5 x 107 viable cells/ml at a cell bleed rate of 0.25 v/d and 2.2 x 107 at 0.1 v/d. These 
concentrations were much higher than for any of the clones tested (Table 1 ). The average 
steady state viable cell density for the clones modified for bcl-2 expression was 1.0 ± 0.24 x 
107 cells/ml at a cell bleed rate of 0.25 v/d and 1.4 ± 0.21 x 107 cells/ml at 0.1 v/d. These 
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Table 1. Steady-state viable cell density, total cell density and viability obtained in perfusion 
culture. 
Dilution Bleed Viable Total Viability 
Rate Rate (cells/ml) (cells/ml) (%) 
(v/d) (v/d) (xlO6) (x 106) 
Vector-only (1) 2.0 0.75 3.18 ±0.31 3.62 ± 0.37 87.6 ± 1.0 
Vector-only (2) 2.0 0.75 3.05 ± 0.42 3.49 ± 0.33 90.6 ± 1.2 
Vector-only (3) 2.0 0.75 2.59 ± 0.36 2.82 ± 0.35 91.8 ±2.0 
Clone 1.1 2.0 0.75 2.41 ± 0.26 2.72 ± 0.28 88.7 ± 2.8 
Clone 2.8 2.0 0.75 5.46 ± 0.26 5.95 ± 0.22 92.0 ± 2.0 Clone 4.2 2.0 0.75 2.80 ± 0.30 3.24 ± 0.35 86.4 ± 1.5 
Vector-only 2.0 0.25 15.3 ±0.8 17.7 ± 1.0 86.1 ±0.9 
Clone 1.1 2.0 0.25 8.12 ±0.44 10.3 ±0.9 76.8 ± 1.3 
Clone 2.8 2.0 0.25 13.3 ± 0.7 16.5 ±0.8 79.0 ± 1.0 
Clone 4.2 2.0 0.25 9.54 ±0.75 11.8 ±0.8 80.9 ±1.8 
Vector-only 2.0 0.1 22.4 ±2.1 28.8 ± 3.8 76.2 ± 1.4 
Clone 1.1 2.0 0.1 12.4 ±0.9 17.4 ± 1.6 71.4 ±2.8 
Clone 2.8 2.0 0.1 15.4 ± 1.1 22.3 ±2.1 69.1 ±2.9 
Clone 4.2 2.0 0.1 12.9 ± 1.1 12.9 ±1.4 80.5 ± 1.9 
results show that bcl-2 expression had a negative effect on the steady state viable cell density 
at cell bleed rates of 0.25 and 0.1 v/d. It was determined that the steady state viable cell 
density of each clone was significantly different from that of the vector-only control with 
95% confidence. These results show that contrary to our expectations, bcl-2 overexpression 
did not lead to an increase in the steady state viable cell density or viability of in perfusion 
culture at dilution rates of 0.25 and 0.1 v/d. 
The cell bleed rates in these reactors were not further reduced after 850 h because the 
viability of the reactors had dropped to about 70% in the bcl-2 expressing cultures without 
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showing improvement in comparison to the vector-only control. In addition, membrane 
fouling was already becoming a problem in the cultures and operating at viabilities below 
70% would not be advantageous for long-term cell culture. 
Analysis of BCL-2 content 
The amount of BCL-2 per cell was analyzed by Western blotting quantitatively 
against a HL-60 standard curve. Clone 1.1 contained a relatively small amount (0.3 
units/cell) of BCL-2 in both of the runs, while clones 2.8 and 4.2 had higher levels (3-7 
units/cell) (Figure 3). One unit of BCL-2 is the amount of BCL-2 content in an HL-60 cell 
(ATCC) at 48 h of batch culture. From previously performed batch experiments (Mowry et 
al., 2001), it was determined that 3-5 units of BCL-2 was enough to cause a decrease in the 
extent of apoptosis and in the cell death rate of H166 hybridoma cells. 
In addition to Western blotting, BCL-2 content was analyzed by flow cytometry to 
ensure that all of the cells in a population were producing BCL-2. The vector-only control 
was used as a negative control for bcl-2 content. Cells that exceeded that fluorescence 
intensity of 98% of the vector-only control cells tested were identified as BCL-2 positive. 
The actual percentage of cells modified for bcl-2 expression that contain BCL-2 may be 
much larger than the percentage gated, but this latter percentage was used as a gauge to 
compare the relative amounts of bcl-2 produced. The cells taken from the perfusion cultures 
of clone 1.1 did not have significantly higher fluorescence intensity than the vector-only 
control. At a high bleed rate (0.75 v/d), only 1.7% of the cells taken from cultures of clone 
1.1 contained BCL-2, while at low cell bleed rates 3.5% of the clones were determined to 
contain BCL-2. Clones 2.8 and 4.2 showed a significant increase in fluorescence intensity 
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due to antibody binding, with greater than 70% of the cells having fluorescence intensities 
that were greater than that of the vector-only controls (Figure 4). BCL-2 content was stable 
throughout the culture period for clones 2.8 and 4.2, and there was no evidence of a non-
producing population developing during these runs. The relative percentage of cells gated is 
in agreement with the results obtained from Western blotting. These results show that clones 
2.8 and 4.2 contain higher levels of BCL-2, which have been shown to reduce cell death due 
to apoptosis in batch culture (Mowry et al., 2001). Clone 1.1 produces a lower level of 
BCL-2 at all cell bleed rates tested. 
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exceed the fluorescence intensity of the vector only control. 
Effect of BCL-2 content on cell density and viability 
After analyzing the amount of BCL-2 content during each of the runs, it is apparent 
that BCL-2 had no effect on viable cell density or viability at a dilution rate of 0.75 v/d. The 
content of clones 2.8 and 4.2 were similar and should have been high enough such that both 
had an anti-apoptotic effect on the H166 hybridoma cells. The steady state viable cell 
density of clone 2.8 was 5.5 x 10* cells/ml, while that of clone 4.2 was only 2.8 x 10* 
cells/ml. The viable cell density of clone 4.2 is not significantly different from that of the 
vector-only control or clone 1.1. Therefore, the increase in viable cell density appears to be 
specific to clone 2.8 and not a result of an increase in BCL-2 content The steady state 
viability at 0.75 v/d showed no correlation with BCL-2 content 
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There was no correlation between the viability or viable cell density and level of 
BCL-2 content at cell bleed rates of 0.25 and 0.1 v/d. As stated earlier the viable cell density 
of the vector-only control was significantly higher than that of any of the clones tested. On 
the other hand, the viable cell density of clone 1.1, the lowest expressing clone, was the 
lowest of all the cultures tested. This suggests that either a low level of BCL-2 content 
causes a decrease in the viable cell density or that populations of cells are better suited to 
adapt and proliferate in perfusion cultures with low cell bleed rates. Regardless, bcl-2 
expression in H166 hybridoma cells did not allow for increased viable cell density or 
viability in perfusion culture at low cell bleed rates. 
Extent of apoptosis 
The extent of apoptosis was examined to determine the importance of apoptosis in 
limiting cell density and to analyze the ability of bcl-2 overexpression to limit cell death via 
apoptosis. The cells were monitored by dual staining with acridine orange and propidium 
iodide and counting apoptotic cells on a hemocytometer. At a cell bleed rate of 0.75, the 
percentage of apoptotic cells did not exceed 1% during the steady state period of cell culture 
for any of the clones tested or the vector-only control (Figure 5a). The percentage of 
apoptotic cells in the vector-only control culture was 0.69 ± 0.08%, while that of the bcl-2 
modified clones was 0.46 ± 0.21% (Table 2). At a cell bleed rate of 0.25 v/d, the percentage 
of apoptotic cells did not change significantly for any of the cultures, remaining below 1% 
for all of the cultures tested. When the bleed rate was decreased to 0.1 v/d, the percentage of 
apoptotic cells increased to 1.2 - 1.4% for all of the cultures tested (Figure 5b). The vector-
only control had a percent apoptosis of 1.3%, while the bcl-2 modified cells had a percent 
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apoptosis of 1.36 ± 0.10%. Because the steady state percentage of apoptotic cells in these 
reactors never exceeded 1.5% for any clone, the rate of apoptosis may not have had a 
significant influence on the viable cell density achieved at any of the cell bleed rates tested. 
The percentage of apoptotic cells showed no trend with the level of BCL-2 content at 
any of the cell bleed rates tested. This suggests that any variation in viable cell density was 
not due to changes in the rate of cell death by apoptosis. This provides further support that 
bcl-2 did not improve cell proliferation of H166 hybridoma cells in perfusion culture. 
Hybridoma cell metabolism and IgM productivity 
The effects of bcl-2 on hybridoma cell metabolism and antibody productivity were 
also examined. The IgM concentrations, which were determined by an ELISA, varied 
significantly for the various cultures tested (Figure 6). At a cell bleed rate of 0.75 v/d, the 
average steady state IgM concentration of the vector-only control cultures was 15.1 ± 6.1 
mg/1, while for the bcl-2 modified clones, it was 18.1 ± 6.9 mg/1. The steady state specific 
IgM production rate for the vector-only control was 1.0 ± 0.5 x 10 * mg/cell/d. This value 
was not significantly different from the specific production rates of any of the bcl-2 modified 
cells (Table 2). At a cell bleed rate of 0.25, the steady state IgM concentration of the vector-
only control was 12.7 mg/1. At 0.1 v/d, the IgM concentration did not reach an apparent 
steady state, but the final concentration was 41 mg/1. These concentrations were much lower 
than the bcl-2 modified cultures, which had average steady state IgM concentrations of 68 + 
43 mg/1 and 80 ± 36 mg/1 at cell bleed rates of 0.25 and 0.1 v/d, respectively. The specific 
IgM production rate for the vector-only control was 1.9 x 10 * mg/cell/d at cell bleed rates of 
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Table 2. Average specific rates of production and consumption during the growth period of 
perfusion culture. 
Run Bleed Rale IgM Glucose Glutamine Lactate Ammonia 
(v/d) (me/ccll/d) (me/cell/d) (me/cell/d) (mg/cell/d) (me/cell/d) 
Vector-Only (1) 0.75 4.7 x 10 * 5.7 x 10-* 3.5 x 10'7 7.0 x 10* 3.0 x 10-8 
Vector-Only (2) 0.75 l J x  l O - 1  7.1 x 10* 3.9 x 107 1.2 x 10' 4.0 x 10"8 
Vector-Only (3) 0.75 1.3 x 10"8 8.3 x 10-6 4 J x 10 7 12 x 10"5 4.1 x 10-8 
Clone 1.1 0.75 1.5 x 10"8 7.4 x 10"6 4.7 x 10-7 1.4 x 10-5 6.0 x 10"8 
Clone 2.8 0.75 8.9 x 10 * 5.0 x 10"6 23 x lO7 5.0 x 10* 1.8 x 10"8 
Clone 4.2 0.75 7.6 x 10 * 9.0 x 10"6 3.7 x 107 1.0 x 10' 2.1 x 10"8 
Vector-Only 0.25 1.9 x 10* 1.3 x lO"6 8.5 x 10"8 1.8 x 10* 9.6 x 10 * 
Clone 1.1 0.25 l.l x 10"8 2.4 x 10* 1.6 x 107 3.0 x 10* 1.3 x 10"8 
Clone 2.8 0.25 1.7 x 10-8 1.5 x 10-6 8.8 x 10"8 2.0 x 10* 8.4 x 10 * 
Clone 4.2 025 7.5 x 10 * 3.7 x 10* 1.6 x 10 7 4.7 x lO"6 1.3 x 10"8 
Vector-Only 0.1 1.9 x 10 * 1.5 x 10* 2.7 x 10-8 1.4 x 10* 6.1 x 10* 
Clone l.l 0.1 9.6 x 10* 23 x 10* 9.9 x 10-8 2.7 x 10* 9.5 x 10 * 
Clone 2.8 0.1 1.6 x 10* 1.7 x 10"6 6.9 x 10-8 1.8 x 10* 7.7 x 10 * 
Clone 4.2 0.1 8.7 x 10 * 3.3 x 10* 12 x 10 7 4.1 x 10* l.l x 10-8 
both 0.25 and 0.1 v/d (Table 2). This value was much lower than any of the bcl-2 modified 
clones tested. Analysis of the bcl-2 modified clones shows no trend in IgM productivity with 
BCL-2 content. Clone 1.1, which contains a low level of BCL-2, has a larger specific IgM 
production than clone 4.2, but a smaller specific production than clone 2.8. An analysis of 
the volumetric IgM productivity shows this same trend (Figure 7). Since there is no 
relationship between BCL-2 content and IgM productivity, it is unlikely that bcl-2 expression 
had an effect on antibody production at cell bleed rates of 0.25 or 0.1 v/d. These results 
show that bcl-2 expression had no effect on antibody production in perfusion culture. 
The specific rates of glucose and glutamine consumption were analyzed to determine 
whether bcl-2 affects cell metabolism (Table 2). There was not a difference between the 
glucose and glutamine concentrations of the vector-only control, clone 1.1 (low BCL-2 
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content) and clone 2.8 (high BCL-2 content) cultures. This suggests that bcl-2 did not have a 
significant effect on nutrient consumption. However, growth of clone 4.2 led to a decrease in 
the glucose and glutamine concentrations throughout the run. This may be due to increased 
nutrient requirements caused by increased levels of BCL-2 content, but is more likely 
specific to this clone. The level of BCL-2 content is similar to that expressed by clone 2.8, 
but clone 2.8 did not demonstrate increased rates of nutrient consumption. Analysis of 
lactate and ammonia expression in the different cultures showed a similar trend with 
increased in concentrations of both metabolites in the medium at the low cell bleed rates. It 
should also be noted that the glucose and glutamine concentrations for all cultures were close 
to that of the feed media, and were significantly higher than that seen during the decline 
phase of batch culture (Mowry et al., 2001). This suggests that nutrients were not limiting at 
any of the cell bleed rates tested. 
Effect of bcl-2 on cell cycle 
The cell cycle distribution of H166 hybridoma cells was analyzed throughout the 
culture period in order to study the effect of bcl-2 on cell cycle progression. It has been 
suggested that bcl-2 prevents cells from entering apoptosis by blocking the transition from 
G1 to S phase (Simpson et al., 1999). The percentage of cells in the Gl, S and G2/M phase 
were determined by staining with propidium iodide and analyzing with flow cytometry. At 
all cell bleed rates, the percentage of cells in Gl phase at steady state was not significantly 
different from that of the vector-only control (Figure 8). At a cell bleed rate of 0.75 /d, 54% 
of the vector-only control cells were in Gl phase, while 55% of the bcl-2 modified cells were 
in Gl phase. As the cell bleed rate was reduced in these cultures from 0.75 to 0.1 v/day, 
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there was a slight increase in the percent of cells in Gl phase and there was little difference 
between the bcl-2 expressers and the vector-only control. In continuous cultures of 
hybridoma cells, Simpson et al. (1999) found that at a dilution rate of 0. 2 v/d the percentage 
of cells in Gl phase was 80%, compared to 56% for the control cell line. This value of 56% 
is similar to results found for the H166 hybridomas in this study. Batch studies showed that 
bcl-2 expression did not alter cell cycle progression in H166 hybridoma cells that exhibited 
an anti-apoptotic response. Therefore, it was not surprising that bcl-2 expression did not 
affect cell cycle progression in perfusion culture. 
CONCLUSIONS 
At a cell bleed rate of 0.75 v/d, bcl-2 expression had no effect on cell density, 
viability, or the extent of apoptosis, as expected. At this cell bleed rate the conditions are 
favorable for cell growth and the extent apoptosis remained low. Since the extent of 
apoptosis remained low, bcl-2 expression was unlikely to have a positive effect on cell 
density. The viable cell density of one of the bcl-2 modified clones was significantly greater 
than that of the vector-only control, but this increase appears to be specific to that particular 
clone and not the result of bcl-2 expression. In addition, bcl-2 had no effect on antibody 
production or cell metabolism at a cell bleed rate of 0.75 v/d. There was also no difference in 
cell cycle distribution between the BCL-2 expressing and non-expressing clones. 
At lower cell bleed rates of 0.1 and 0.25 v/d, there were no differences between the 
high and low expressing bcl-2 clones, although the viable cell density in the vector-only 
control was significantly greater than that of the bcl-2 expressing clones. Viable cell density 
showed no trend with the amount of BCL-2 content, although the concentration of the vector-
106 
only control was significantly higher than any of the bcl-2 modified clones. This suggests 
that bcl-2 may cause a decrease in viable cell density even at low levels of expression. It is 
also possible that the vector-only control was better suited to adapt to perfusion culture at 
low cell bleed rates due to culture variation and that bcl-2 itself did not cause the decrease in 
viable cell density. Regardless, bcl-2 overexpression did not lead to an increase in viable cell 
density in perfusion culture at low cell bleed rates, as was hypothesized. In addition, bcl-2 
expression had no effect on viability or the extent of apoptosis at cell bleed rates of 0.1 and 
0.25 v/d. h fact, the percentage of apoptotic cells remained low at all cell bleed rates tested, 
which may suggest that cell death occurred by other factors, presumably necrosis. The 
volumetric antibody productivity did increase in the bcl-2 modified clones, but this 
difference was more likely due to culture variation than bcl-2 expression since the specific 
antibody productivity shows no trend with BCL-2 content. Bcl-2 expression did not alter cell 
metabolism or cell cycle distribution. These results suggest that bcl-2 is not effective in 
increasing the productivity of H166 hybridoma cells in perfusion culture. 
Apoptosis did not appear to be a significant cause of cell death in perfusion culture 
even when the viability of the cultures dropped to approximately 70%. It is possible that the 
pumps and other equipment needed for perfusion by external hollow fiber membranes may 
have caused a significant amount of cell death, as the result of necrosis. It may be necessary 
to decrease the rate of cell death from necrosis in order to take advantage of a decrease in 
apoptosis due to bcl-2 expression. In addition, the H166 hybridomas used in this study had a 
limited amount of protection from apoptosis in batch culture as compared to other hybridoma 
cell lines (Itoh et al., 1995; Simpson et al., 1997; Mowry et al., 2001). To determine if bcl-2 
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overexpression can lead to improvements in cell density, viability, and antibody productivity, 
other cell lines grown in less stressful conditions should be tested. 
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CHAPTER 4. GENERAL CONCLUSIONS 
GENERAL DISCUSSION 
The studies that have been performed suggest that BCL-2 decreases cell death by 
blocking apoptosis at levels of BCL-2 content greater than 2 units/cell, where a unit/cell was 
defined to be the amount of bcl-2 content in an HL-60 cell taken at 48 h of batch culture. 
One of the major problems encountered in these studies was obtaining stable inter-run 
expression. The amount of bcl-2 produced by the clones varied significantly, which allowed 
us to examine the effect of bcl-2, but for industrial application of this technology stable 
expression of bcl-2 will be necessary. Other investigators have stated that they have obtained 
stable expression of bcl-2, but they do not examine whether the level of expression remains 
constant throughout the runs. For bcl-2 to be applied industrially this problem will have to 
be addressed. 
With respect to the H166 hybridoma cell line in particular, the use of bcl-2 to improve 
antibody productivity does not appear to be a valid approach since the production of IgM 
drops off after 6-8 days in culture regardless of the amount of bcl-2 expressed. The cells 
that express bcl-2 maintain a higher viability than the non-expressers studied in batch culture, 
but they still stop producing antibody after 6-8 days. Other investigators have found 
dramatic increases in the amount of antibody produced by cells that overexpress bcl-2 (Itoh 
et al., 1995; Simpson et al., 1997). This increase may be caused by an increase in the 
productive period of cell culture or by an increase in the specific antibody productivity. 
The effect of bcl-2 on viable cell density and specific antibody productivity appears 
to be cell line specific. The cell lines that others have studied appear to be more susceptible 
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to apoptosis in general. Itoh et al. (1995) found that the viability of 2E3 hybridoma cells 
remained above 50% until 6-7 days in culture and that bcl-2 overexpression was able to 
extend this to 10-11 days. Bcl-2 overexpression in TB/C3 cells was able to increase the 
membrane intact period from 3-4 days to 9 days (Simpson et al., 1997). The viability of the 
HI66 hybridoma cells used in this study remained above 50% until 9-10 days and bcl-2 
overexpression was able to increase this period to greater than 12 days at the highest level of 
BCL-2 content. The other cell lines lose viability sooner with a more dramatic decrease in 
viability. In these cell lines bcl-2 was able to increase the volumetric antibody productivity 
and caused a more dramatic improvement in the viable period of cell culture. These results 
show that bcl-2 overexpression may be of greater use in hybridoma cell lines that are 
susceptible to apoptosis earlier in the culture period. It should also be noted that differences 
in culture conditions could have led to some of these differences. 
In addition to differences in the effect of bcl-2 on cell proliferation, bcl-2 expression 
led to large differences in antibody productivity among the cell lines tested. Bcl-2 expression 
in the 2E3 hybridomas led to greater than a 2 fold increase in the specific antibody 
productivity, although antibody concentrations of both the bcl-2 modified and control 
cultures leveled off after about 8 days in culture. This was similar to the results seen for the 
H166 cell line used in this study. For the TB/C3 cell line, the productive period of batch 
culture was increased in the bcl-2 modified cell line. This cell line was able to maintain 
antibody production in batch culture for about 6 days, while the control cell line maintained 
production for only 4 days. The antibody concentration was lower than the control for the 
first 4-5 days and the final concentration was less than 0.5 times greater than that of the 
control cell line. These results are actually very similar to those seen for the H166 
112 
hybridomas in that the antibody concentration leveled off in all the cultures even while 
greater than 50% of the cells remained still viable (membrane intact). 
We also analyzed the effect of bcl-2 on the productivities in high cell density 
perfusion culture. The results showed that bcl-2 does not improve the viability or the culture 
productivity for this cell line. Studies in Appendix B show that apoptosis played a large role 
in cell death of H166 hybridoma cells in perfusion cultures with total cell retention. The 
results of our studies at cell bleed rates as low as 0.1 v/day shows that the cells may die from 
factors other than apoptosis, presumably necrosis. We believe that the high stresses to which 
the cells are exposed in the reactor system cause the cells to die via necrosis. At extremely 
low cell bleed rates there was a slight increase in the percent of cells undergoing apoptotic 
cell death, but the viability of the cell culture had already dropped below 75%. It would not 
be advantageous to operate the reactors below a viability of 75% because at this level of 
viability, accumulating cell debris starts to cause problems with the membrane flux. 
Although the H166 cells respond to the overexpression of bcl-2 with decreased apoptotic 
death in batch culture, there is no effect of bcl-2 expression on apoptotic death in perfusion 
culture. It is not known if this lack of an anti-apoptotic effect of bcl-2 overexpression is cell 
line specific. Previous researchers have seen a limited advantage to using bcl-2 in perfusion 
cultures when operated at total cell retention. However, the results of this study suggest that 
use of bcl-2 expressing cell lines in long-term perfusion cultures would not be advisable for 
this cell line and others like it. Instead, the pursuit of a means of inhibiting death by necrosis 
might be productive. 
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RECOMMMENDATIONS FOR FUTURE WORK 
Due to the absence of increased antibody productivity in batch or perfusion cultures, 
further work with bcl-2 overexpression in this cell line is not advisable. A better approach 
would be to examine alternative ways of increasing antibody productivity. Another option 
would be to study the effect of bcl-2 in other hybridoma cell lines in order to determine if the 
benefits of bcl-2 are cell line specific. In addition, it may be valuable to investigate the role 
of bcl-2 in other mammalian cell types, such as CHO cells. 
In perfusion culture, bcl-2 expression did not lead to improved cell densities or 
antibody yields. It was determined that the amount of apoptosis in the cultures remained low 
throughout the culture period, and it is believed that necrosis may have played a large role in 
cell death. Analysis of less stressful methods of obtaining perfusion may allow for improved 
cell densities and antibody yields. In addition, bcl-2 overexpression may further improve 
antibody productivities in perfusion cultures with reduced levels of necrosis. 
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APPENDIX A. ADDITIONAL PERFUSION STUDIES 
Design of the perfusion reactor 
A full description of the perfusion reactors used for the studies in this thesis is 
provided in chapter 3. A diagram of the reactor setup is shown in Figure 1 and a photograph 
of the entire system is shown in Figure 2. 
Sampling 
Feed and Effluent 
Pump Recirculation Pump 
Hollow Fiber 
Membrane 
Cell Free Bleed 
Effluent 
Reservoir 
Medium 
Reservoir 
Bioreactor 
Magnetic 
Stirrer 
Figure 1. Diagram of the perfusion reactor used in these experiments. In addition, the 
system has dissolved oxygen control by aeration through a microporous sparger, and pH 
control by the addition of 0.5 M sodium bicarbonate. 
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Figure 2. Perfusion reactor used in this study. 
Growth of hybridomas In perfusion culture at various perfusion rates 
After setting up the perfusion system, the first step was to show the H166 hybridoma 
cells could be grown in perfusion culture and that steady state could be obtained. It was 
hoped that bleed and dilution rates could be determined, which would give steady state viable 
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cell densities greater than 1 x 107. Steady state viable cell densities of 1-2 x 107 viable 
cells/ml have been obtained in other perfusion reactors (Banik and Heath, 1995; Reuveny et 
al., 1986). 
Reactors were initially seeded with 2-3 x 10s viable cells/ml in the 650 ml perfusion 
reactors at a viability of 93%. The cells were grown in batch mode until the viable cell 
densities reached 2.68-3.63 x 106 viable cells/ml, with viabilities ranging from 91-96%. The 
reactors were started in perfusion mode at this point, 2-3 days after the initial seeding (31 h 
after the first sample was taken). The Masterflex pumps were set to provide dilution rates of 
0.73, 1.26, and 1.75 v/d. Initially, the cell free bleed pumps were set so that an expected cell 
bleed rate of 0.4 v/d would be obtained. This value was chosen in order to ensure that dead 
cells would be effectively removed from the system and a steady state could be achieved. 
This bleed rate should also have ensured that cells were given enough time to grow and were 
not washed out of the system. The average dilution and bleed rates obtained are listed in 
Table 1. 
All three of the perfusion reactors reached a local maximum viable cell density at 
about 200 h (Figure 3). After the reactors with dilution rates of 0.73 and 1.26 v/day reached 
a maximum viable cell density, there was a slow downward drift in viable cell density 
without reaching a steady state. The viability always remained above 85% throughout the 
run (Table 1), so it seems unlikely that the downward drift was caused by the cell bleed being 
too low. If this occurred, the viability will drop off rapidly as dead cells begin to build up. 
Initially, it was believed that this was the result of an overshoot, and the viable cell density 
would eventually reach a steady state value. For this reason, the cells were grown in 
perfusion without changing the dilution and bleed rates for 300 hours after the maximum 
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Table 1. Operation of perfusion reactor at various perfusion and bleed rates. 
Average 
Dilution Rale 
(/d) 
Average 
Bleed Rate 
C/d) 
Maximum 
Viable Cell 
Density 
(cell/ml) 
Viability 
(% Range) 
Steady-State 
Viable Cell 
Density® 
(cells/ml) 
Reactor 1 
Initial settings 
After membrane change1 
0.73 
0.73 
036 
036 
6.56 x 106 
634 x 106 
85.1-91.9 
86.6-92.0 
NA 
5.7 x 10* 
Reactor 2 
Initial settings 
After membrane change * 
13 
13 
0.40 
0.30 
1.03 x I07 
1.24 x 107 
85.0-92.8 
78.4-85.6 
NA 
l.l x 107 
Reactor 3 
Initial settings b 
After membrane change * 
1.7 
2.0 
0.44 
033 
8.93 x 106 
1.65 x 107 
86.7-94.1 
85.4-89.4 
NA 
NA 
a) Values do not include the time after changing the hollow fiber membranes or during the highly 
variable region from 600-750 h. 
b) Reactor 3 values do not include the period from 175-300 h that were affected by a feed shutdown. 
c) Steady state is assumed when the viable cell density varied by less than 10% for 6 or more days. 
viable cell density was achieved. Another possibility is that the flowrates could have been 
changing throughout the run due to fouling of the hollow fiber membranes or wearing of the 
tubing in the peristaltic pump. Vits and Hu (1992) suggested that fluctuations in the cell 
density were due to the retention ratio, the ratio of the cell bleed rate to the dilution rate. The 
variations in the bleed rates were less that 2.5% for both of the two reactors from 200-500 h, 
and they do not have any trend. The dilution and bleed rates were determined by measuring 
the volume of the cell free and cell containing bleed every couple of days. Since there was 
no trend in the flowrates, it seems unlikely that this was the cause of the downward drift in 
the viable cell density. Another possibility is that the metabolism of the cells was changing 
with time. Growth of the cells at the low growth rates of perfusion culture may have caused 
the cells to switch to a metabolism where the growth rate was even further reduced. 
The reactor with a dilution rate of 1.75 v/d had a large drop in the viable cell density 
after 175 h due to pumping problems. The feed to this reactor stopped flowing from 175-
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Figure 3. Viable cell density of H166 hybridoma cells achieved in perfusion culture at 
various dilution rates. 
200 h, causing a large drop in both the viability and the viable cell density. As a result, the 
reactor did not reach a second peak in the viable cell density until after 335 h. At this point, 
there was a slow downward drift in the viable cell density similar to the other reactors. Since 
steady state was never achieved, the maximum viable cell density was used to compare the 
three reactors (Table 1 ). The largest viable cell density achieved at a cell bleed rate of 
approximately 0.4 v/day was 1.03 x 107 cells/ml at a dilution rate of 1.26 v/day. At first 
glance, this seems surprising because one would expect the highest viable cell density to 
occur at the highest dilution rate, 1.75 v/day. One question is whether the cell density in this 
reactor was as high as it would have been if there had not been flow problems. Prior to 
175 h, the cell density in the 1.26 v/day reactor was already higher than the 1.75 v/day 
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reactor. The reason for the higher viable cell density in the 1.26 v/day reactor is that the cell 
bleed rate was lower. The reactor with a dilution rate of 1.26 v/day had a cell bleed rate of 
0.40 v/day, while the reactor with a dilution rate of 1.75 v/day had a cell bleed rate of 0.44 
v/day. It appears that the viable cell density was controlled more by the bleed rate, than by 
the dilution rate in these reactors. Since the viability of the reactors was so high and the 
viable cell density of the 1.75 v/day reactor is lower than the 1.26 v/day reactor, it is likely 
that there were enough nutrients in this reactor to support more cells. For this reason, the cell 
bleed rate was reduced to approximately 0.3 v/day in order to determine if higher densities 
could be obtained. The hollow fiber membranes were changed for all three reactors in order 
to ensure that fouling did not become a problem during the second half of the experiment. 
The reactor with the lowest dilution rate, 0.73 v/day, also had the lowest maximum 
viable cell density, 6.6 x 106 cells/ml, even though the cell bleed rate was lower than the 
other two reactors. The lower cell bleed rate should have led to higher cell densities in the 
absence of nutrient or metabolite limitations. The dilution rate appears to have controlled the 
cell density in this reactor. 
In addition to the cell densities, the antibody concentrations in the reactors were also 
determined throughout the run by size exclusion chromatography (Figure 4). After 
150 h, when the cells had time to reach high cell densities, the antibody concentrations varied 
between 75 and 125 pg/ml for the different reactors. The concentrations were highly 
variable throughout this range of concentrations, due to experimental error and changes in the 
viable cell density. The reactor with a dilution rate of 1.26 v/day had a slightly higher 
antibody concentration than then other two, but they all fluctuate around 100 pg/ml. 
Assuming a concentration of 100 pg/ml, antibody productivities up to 175 mg/1 culture per 
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Figure 4. Determination of IgM concentration in perfusion culture. (A) IgM concentration at 
various dilution rates. (B) Standard curve for IgM concentration determined by size 
exclusion HPLC. 
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day were obtained. In batch culture, the antibody productivity of these H166 hybridoma cells 
was up to 6 mg/1 culture per day (Data not shown). The perfusion reactors had 30 times the 
antibody productivity of batch reactors, which is similar to that found by Reuveny et al. 
(1986). 
After 500 h in culture, the viable cell densities continued to decrease slowly and it 
was concluded that steady state would not be achieved. The hollow fiber membranes were 
changed in order to ensure that permeate flow was not restricted during the remainder of the 
experiment. At this point, 40 ml of medium was quickly pumped into the reactors in order to 
replace the medium lost when the membranes were replaced. The average dilution rates of 
0.73 and 1.26 v/day remained the same, while the dilution rate of the third reactor was 
increased from 1.75 to 2.0 v/day. This was done with the hope that higher viable cell 
densities could be obtained at a higher dilution rate. The intention for the second half of this 
experiment was to decrease the bleed rate to 0.3 v/day for each of the three reactors. The 
average cell bleed rates are listed in Table I. 
After the hollow fiber membrane was changed, there was a quick increase in the 
viable cell density of all three reactors (Figure 3). The change in the cell density occurs 
more quickly than could be explained by the change in the cell bleed rate alone. This was 
likely due to the quick removal of 40 ml of cells and addition of 40 ml of media to each of 
the reactors, which led to an increase in the specific growth rate. This suggests that it may be 
beneficial to occasionally quickly remove and add cells from a perfusion reactor to cause the 
cell density to jump. As illustrated by de la Broise (1992), hybridomas in perfusion culture 
represent a "grow or die" culture. It may be possible to obtain higher cell densities by 
occasionally stimulating the cells to grow. 
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During the second half of the experiment, there were extreme flowrate fluctuations in 
the reactors with dilution rates of 0.73 and 2.0. The main reason for this was due to 
deformation of the tubing at the pump heads. After it was replaced at approximately 700 h, 
this was no longer a problem. Steady state viable cell densities were obtained at dilution 
rates of 0.73 and 1.26 v/day. Steady state was assumed when the viable and total cell 
densities varied by less than 10% for a period of at least 6 days, with no observable trend. 
These steady state viable cell densities were 5.72 x 10* and 1.12 x 107 cells/ml, respectively. 
While steady state viable cell densities could not be achieved at a dilution rate of 2.0 v/day, a 
maximum value of 1.65 x 107 cells/ml was obtained. Viabilities for all three reactors 
remained above 78% throughout the run. The maximum viable cell densities follow the 
expected trend; the reactor with the largest dilution rate also had the largest maximum viable 
cell density. 
At a dilution rate of 0.73 v/day, there was not a significant change in the cell bleed 
rate. The maximum viable cell densities and viabilities were similar, but a steady state was 
achieved in the second half of the experiment. At a dilution rate of 1.26 v/day, the average 
bleed rate was decreased from 0.4 to 0.3 v/day. This reactor proved to be the most stable 
throughout the entire run. The decrease in the bleed rate led to an increase in the maximum 
viable cell density from 1.03 x 107 to 1.24 x 107 viable cells/ml (Table 1), while the viability 
decreased from an average value of 88.9% to 82.0%. These bleed rates are fairly high, which 
suggests that even greater cell densities could be achieved at lower cell bleed rates. The third 
reactor had changes in both the dilution and the bleed rates. At an increased dilution rate and 
a decreased bleed rate, the maximum viable cell density increased greatly, as expected (Table 
1). The viability decreased only slightly from an average of 90.4% to 87.4%. This also 
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suggests that greater viable cell densities could be reached at lower cell bleed rates. Steady 
state was never achieved in this reactor, although it appears that steady state was being 
approached (Figure 3). 
In the first half of the experiment, all of the reactors failed to reach steady state, while 
in the second half they had either reached steady state or were approaching steady state when 
the run was stopped. The reason for this is somewhat unclear. The flowrates were equally as 
stable during the first half of the experiment as they were when steady state was achieved at 
the end. There were no obvious trends in the flowrates, which would suggest a downward 
drift in the viable cell density as seen in the first half of the experiment. The one change 
made in all of the reactors was that the membranes were changed. Membrane fouling could 
have led to an increase in the pressure drop across the membrane. This may have adversely 
effected the cells, although one would expect a decrease in the viability to accompany the 
decrease in viable cell density. It is possible that the increased pressure drop may lead to 
arresting of cell growth. 
Regardless of the reason for the difficulty in achieving steady state, much care should 
be taken in controlling the dilution and bleed rates. Large fluctuations in cell density and 
viability have been observed when the flowrates fluctuate slightly. In addition, the 
membrane should be well cleaned to ensure there is no adverse effect on cell growth. 
Apoptosis in hybridoma perfusion culture with high cell retention 
Many authors have noted that cell death due to apoptosis occurs spontaneously in B 
cell hybridoma cultures, even under normal conditions (Chung et al., 1997; Mercille and 
Massie, 1994; Soliz-Recendez et al., 1995). The work of other authors has suggested that 
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hybridomas whose growth rate is inhibited by thymidine treatment die quickly as the result of 
apoptosis (Simpson et al., 1997). This low growth state is similar to that seen in perfusion 
cultures at high cell retention. This experiment was designed to show that apoptosis is the 
primary mode of cell death in perfusion culture. In order to cause cell death, cells were 
grown at very high cell retention, which is known to lead to low viabilities and eventually to 
the shut-down of the system. 
H166 hybridoma cells obtained from Abbott Laboratories were grown in the 
homogeneous perfusion. Each of three reactors were seeded with 2 x 10s viable cell/ml in a 
650 ml working reactor volume, at a viability of 87%. Reactors were started in perfusion 
mode after running for 70 h in batch culture, when the viable cell density grew to over 2 x 
106 cells/ml, with viabilities greater than 88%. 
The Masterflex pumps were set to provide average dilution rates of0.35,0.58 and 
1.05 v/day, respectively. These dilution rates remained fairly stable throughout the culture 
period. The cell-free bleed from each reactor, the permeate from the membrane cartridge in 
the recirculation loop, was set to approximately 90% of the dilution rate. This should 
provide a high enough level of cell retention such that if dead cells begin to build up in the 
system, steady state would not be achieved and the cells would eventually all die. The 
average dilution and cell bleed rates are listed in Table 2. It should be noted that the cell 
bleed rates are average values and were highly variable throughout the run. This variability 
was not of significant concern since achieving steady state was not the objective of the 
experiment. 
Cell densities and viabilities were determined by staining the cells with Erythrosin B 
and counting on a hemocytometer, while the extent of apoptosis was determined by 
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Table 2. Operation of perfusion reactor at high cell retention. 
Average 
Dilution Rate 
(/d) 
Average 
Bleed Rate 
(/d) 
Maximum Viable 
Cell Density 
(cells/ml) 
Maximum Total 
Cell Density 
(cells/ml) 
Reactor 1 0.35 0.16 4.48 x 106 6.41 x 106 
Reactor 2 0.58 0.05 4.63 x 10* 9.41 x 106 
Reactor 3 1.05 0.19 7.14 x 106 1.06 x 107 
fluorescently labeling the DNA strand breaks, which are indicative of apoptosis, using the 
Apoptag Direct Kit (Oncor), and quantifying by flow cytometry. The viabilities remained 
high for the first 100-150 h of culture, and then began to drop off quickly (after 
approximately 50 h in perfusion) (Figure 5). The viable cell densities grew to 4.48 x 106, 
4.63 x 106, and 7.14 x 106 cells/ml, for each of the three reactors. It leveled off after about 
200 h in culture and then began to drop off quickly. These values are much lower than seen 
in the previous experiment. This is likely due to the relatively low dilution rates that were 
used in this experiment. Also, since the cells were immediately grown at such a high cell 
retentions when perfusion was initiated, there was not enough time for viable cell densities to 
build up. Reactors were continued in perfusion mode until the viabilités dropped to below 
40%. 
The percent of apoptotic cells correlates very closely to the percent of non-viable 
cells (Figure 6), indicating that apoptosis is the primary mode of cell death in high cell 
retention perfusion cultures. In two of the reactors, the percentage of apoptotic cells is 
actually greater than the percent of non-viable cells. While experimental error may 
contribute to this, the discrepancy is likely a result of the fact that DNA fragmentation begins 
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Figure 5. Viable cell density of H166 cells at various dilution rates with nearly total cell 
retention. 
before the cell membrane becomes permeable. Cells that exclude Erythrosin B dye, and thus 
appear viable, could actually be apoptotic. This method counts all of the apoptotic cells in 
the population, both viable and non-viable. This number is different from that determined by 
acridine orange/propidium iodide staining, which allows for determination of both 
viable/apoptotic and non-viable/apoptotic cells. 
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Figure 6. Comparison of apoptotic and non-viable cells in perfusion culture at nearly total 
cell retention. (A) 0.35 v/d (B) 0.58 v/d (C) 1.05 v/d. 
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APPENDIX B. DEVELOPMENT OF HYBRIDOMA CELLS WITH VARIOUS 
LEVELS OF BCL-2 EXPRESSION 
Attempt to obtain H166 cells with inducible bcl-2 expression 
The purpose of this project is to determine the effect of various levels of BCL-2 
content on hybridoma cell death and antibody productivity. The first step in this process was 
to obtain cells with various levels of BCL-2 content. Initially, an attempt was made to 
develop a cell line with inducible bcl-2 expression, using the Clontech tet-off gene expression 
system. There was a significant amount of progress, but a clone with inducible bcl-2 
expression was not obtained. Clones with constitutive bcl-2 expression using the 
pcDNAS. l/hygro(-) expression vector were developed in order to study the effect of BCL-2 
content on hybridoma cell proliferation. These clones were discussed in the preceding 
chapters which they were used for experiments in both batch and perfusion culture. 
Use of the Clontech tet-off gene expression system 
The Clontech tet-off gene expression system allows for the inducible on/off control of 
bcl-2 expression in the presence of tetracycline. Four different plasmids are used in order to 
obtain inducible bcl-2 expression in the hybridoma cells. These plasmids are pTet-off, 
pBcl2UHD, pTRE, and pTK-Hyg (Figure 1). 
The hybridoma cells were initially transfected with the pTet-off plasmid, which 
produces a hybrid protein known as the tetracycline response transcriptional activator (tTA). 
This protein contains portions of both the Tet repressor (TetR) and the VP16 protein of 
herpes simplex virus, and acts as a transcriptional activator in the absence of tetracycline. 
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Figure 1. Diagrams of the plasmids used in the pTet-off gene expression system. (A) pTRE 
(B) pBcl2UHD (C) pTet-Off (D) pTK-Hyg. 
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Positive clones were selected for in the presence of G418 selective antibiotic. 
Next, the hybridomas were co-transfected with either pTRE or pBcl2UHD, and pTK-
Hyg plasmids. The pBcl2UHD plasmid was generously donated by Dr. Dong X. Yin, 
Stanford University. This plasmid contains the cDNA for human bcl-2 and is used in order 
to generate hybridomas with bcl-2 expression. This plasmid contains seven copies of the 42-
bp tet operator sequence located just upstream of a minimal CMV promoter. This plasmid 
lacks the strong enhancer normally associated with the CMV promoter, h the absence of 
tetracycline, the tet repressor binds to the tet operator sequence and thereby activates 
transcription. The pTRE plasmid is similar to the pBcl2UHD plasmid, but lacks the bcl-2 
cDNA insert. This plasmid was to be used as a negative control. The plasmid pTK-Hyg 
provides hygromycin resistance to the hybridoma cells so that positive clones could be 
selected for in the presence of hygromycin B. Once double stable clones were obtained, 
BCL-2 content was analyzed by Western blotting. The objective was to obtain clones with 
low background and high tetracycline induction of bcl-2. An overview of the Clontech tet-
off gene expression system is shown in Figure 2. 
Progress made In an attempt to obtain double stable cell line 
After showing that apoptosis is the major cause of cell death in a perfusion reactor at 
near total cell retention, the next step was to generate bcl-2 producing clones with the 
Clontech tet-off gene expression system. Plasmid DNA was obtained by transforming XL-1 
blue E. coli and isolating the DNA. The DNA was isolated by extracting with 
phenol/chloroform and precipitating with 20% polyethylene glycol. Sufficient quantities of 
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^ pTet-off plasmid 
Tet-off cell line growing ie HSFM 
with 15% FBS and G418 antibiotic ' 
Co-transfect with pBcl2UHD or pTRE 
Select hygromycin B resistant clones 
Screen clones for low background and 
high tetracycline induction of bcl-2 
pTK-Hyg z-> 
plasmid v—^ 
pBcl2UHD 
Double stable Tet-olf cell line growing 
in HSFM with 15% FBS, G418 and 
Hygromycin B 
Figure 2. Overview of developing a double stable Tet-off H166 hybridoma cell line. 
pTet-off, PTRE, pBcl2UHD and pTK-Hyg plasmids were isolated to use in transacting the 
H166 hybridoma cells. 
Trans fecting the H166 hybridomas proved to be more difficult than expected. 
Initially, lipofectamine (Gibco BRL) was used in an attempt to transfect the hyridoma cells. 
SV40 LacZ plasmid was used to determine transfeetion efficiency. Expression of the SV40 
LacZ plasmid was detected by assaying for (3-galactosidase. One ml of cells were seeded in 
35 mm Coming tissue culture plates (Fisher Scientific) at cell densities ranging from 2-5 x 
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106 cell/ml. Lipofectamine concentrations of 2-10 pl/ml and SV40 lacZ plasmid 
concentrations of 1-3 fig/ml were tested in an attempt to transfert the H166 hybridomas. 
Cells were grown in HSFM with the lipofectamine and the plasmid DNA for 2-16 hours and 
were switched to HSFM with 15% FBS after that time. Cells were allowed to grow for 2 
days and were then viewed under the microscope to determine whether there were any 
transfectants. Transfected cells should have stained blue in the presence of X-gal staining 
solution. After several unsuccessful attempts to transfert the H166 hybridomas, this method 
was abandoned. 
Next, a BTX 600 electro cell manipulator was used to transfert the H166 hybridoma 
cells by electroporation. A small number of cells, transfected with SV40 LacZ, stained 
positive for P-galactosidase production in the first experiment. While this process was 
optimized, it never provided transfeetion efficiencies greater than 1%. Since the plasmids 
used to obtain bcl-2 expression contain selectable markers, transfected cells can be obtained 
even with these low transfeetion efficiencies. 
In order to use the selectable markers to isolate transfected cells, the concentrations of 
G418 and hygromycin B that are lethal to H166 hybridoma were determined. In separate 
experiments, cells were grown in concentrations of G418 and hygromycin B ranging from 0 
to 800 ng/ml. Cells were grown in 35 mm tissue culture dishes (Corning) for seven days in 
HSFM with 15% FBS. Medium was changed on days 3 and 6 by removing 1 ml of the cell 
suspension and adding 1 ml of media. Viable and total cell densities were determined for 
each of the samples by counting on a hemocytometer with Erythrosin B. It was determined 
that 600 pg/ml G418 and 400 ng/ml hygromycin B were lethal to the cells (Figure 3). 
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Figure 3. Toxicity test on H166 cells to determine the optimal level of selection antibiotic to 
obtain stable clones. (A) G418 (B) Hygromycin B. 
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Cells were then transfected with plasmids from the Clontech tet-off system by 
electroporation. Cells were first electroporated with the pTet-off plasmid. This plasmid 
contains a selectable marker for antibiotic resistance to neomycin or geneticin (G418). The 
electroporated cells were incubated in selection medium containing HSFM with 15% FBS 
and 600 pg/ml G418, two days after electroporation. These cells were periodically fed with 
the selection medium for a period of 2-3 weeks, so that all of the untransfected cells would 
die. Cells were then counted on a hemocytometer and 100 pi aliquots were added to 96 well 
plates at a seeding density of 0.5 cells/well. After two weeks, growing clones were moved to 
12 well plates in 2 ml of selection medium. Forty of these clones, which are designated as 
H166 / pTet-off clones, were grown in 75 cm2 T-fiasks. They were then stored as frozen 
aliquots at -140°C in HSFM with 15% FBS and 10% dimethyl sulfoxide for later use. 
After the H166 / pTet-off clones were obtained, the next step was to transfert them 
with pBcl2UHD or pTRE (control plasmid). To obtain stable transfectants, the cells were co-
transfected with pBcl2UHD (or pTRE) and pTK-Hyg. PTK-Hyg contains a selectable 
marker that provides transfected cells with antibiotic resistance to hygromycin B. Two days 
after electroporation with pBcl2UHD (or pTRE) and pTK-Hyg, the cells were grown in 
selection medium containing HSFM with 15% FBS, 600 pg/ml G418 and 400 pg/ml 
hygromycin B. Cells were cloned in 96 well plates and were then moved to 75 cm2 T-fiasks. 
These cells were frozen in aliquots at 140 °C in HSFM with 15%FBS and 10% dimethyl 
sulfoxide for later use. Approximately 10 clones containing pBcl2UHD and 1 clone 
containing pTRE were obtained for each of 4 different H166 / pTet-off clones. These clones 
are identified as HI66 / pTet-off(Clone #) / pBcl2UHD(Clone #). 
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After the bcl-2 clones were obtained, various methods were used to determine if bcl-2 
was expressed and to determine the level of expression in each of these clones. Initially, 
fixed cells were incubated with FITC conjugated BCL-2 antibody and analyzed by flow 
cytometry to check for human BCL-2 protein. The fluorescence intensity of cells transfected 
with pBcl2UHD should have been greater than both pTRE clones and untransfected cells. 
There was no difference in the fluorescence intensity of the cells modified for bcl-2 
expression and the control cell lines. Cells that contained BCL-2 could not be isolated since 
if there was any production it was below the sensitivity of the assay. 
In addition to flow cytometry, Western blotting was used in order to determine if the 
clones were producing BCL-2. Samples were run on 12.5% polyacrylamide gels, with a 5% 
stacking gel. After transferring the bands to nitrocellulose, the gel was incubated with 1 
mg/ml BCL-2 (Ab-1) antibody for 2 hours. The membrane was then incubated with protein 
A-horseradish peroxidase, and then with ECL substrate, so that BCL-2 bands could be 
visualized when exposed to film. After exposing the nitrocellulose to film, no bands 
appeared except for the HL-60 cells that were used as a positive control for BCL-2 content. 
After the flow cytometry and Western blotting failed to identify clones with BCL-2 
content, the cells were checked for RNA expression by RT-PCR. First, the cells were 
checked for expression of the RNA for the tetracycline response transcriptional activator 
protein (tTA). An agarose gel of various clones, which expressed some level of tTA, is 
shown in Figure 4. Numerous clones that expressed the tTA protein were isolated and were 
then transfected with pBcl2UHD and pTK-Hyg. RT-PCR was then use to check the double 
stable transfectants for bcl-2 expression. Similar to the Western blotting results, none of the 
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Figure 4. RT-PCR to check H166/pTet-Off clones for expression of the tetracycline-response 
transcriptional activator (tTA) protein, which allows for controlled expression in the pTet-off 
system. CHO-AA8-luc cell lysates (Clontech) were used as a positive control. 
double stable clones tested showed any signs of bcl-2 expression. After testing over 200 
clones for bcl-2 expression by a variety of methods, it was necessary to take an alternative 
approach to obtain cells with different levels of BCL-2 content. 
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Development of a constitutive expression vector for bcl-2 
After numerous attempts to obtain a cell line with inducible bcl-2 expression failed, 
the focus turned to obtaining numerous clones, each with a different level of BCL-2 content. 
The method used to obtain these clones is provided in Chapter 2. Briefly, the cDNA 
sequence for bcl-2 was removed from pbcl2UHD and ligated into the multiple cloning site of 
pcDNA3.1 /hygro(-) (Figures 5 and 6). To ensure that the correct cDNA was properly 
inserted into the multiple cloning site, the DNA sequence was determined at the ISU DNA 
sequencing facility. The H166 hybridomas were then electroporated with this bcl-2 
expression vector (pcDNA3. l/hygro(-)/bcl-2) and selected for in the presence of G418 
antibiotic. Stable clones were isolated by dilution cloning. 
RT-PCR was used to screen a large number of clones for bcl-2 expression. Ten out of 
50-60 clones tested were shown to express some level of BCL-2 (Figure 7). Western blotting 
was then used to determine which of these ten bcl-2 clones to use in future experiments. The 
Western blotting procedure used is listed in chapters 2 and 3. Clones with various levels of 
BCL-2 content were chosen for future use. Figure 8 shows an example a western blot used in 
the final selection of bcl-2 expressing clones. These clones were later used in the 
experiments shown in chapters 2 and 3. 
Effect of pH on decline phase of cell cycle 
During the growth of the H166 pcDNA3.1 /bcl-2 clones in batch culture it became 
apparent that clone 4.2 exhibited a quick decrease in viability during the decline phase of 
batch culture, but it was noted that this drop coincided with a rapid decrease in the pH. To 
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Figure 5. Diagram of the pcDNA3.1/Hygro(-) plasmid (Invitrogen). 
determine if this decline in viability was the direct result of the pH drop, clone 4.2 in addition 
to the vector-only control were grown in batch culture with pH control. It was determined 
that the viable cell density and viability of clone 4.2 declined more slowly when the pH was 
maintained above 7 (Figures 9). The rate of viable cell decline did not change for the vector-
only control, although pH control did allow it to reach a slightly higher viable cell density. 
For the first 8 days of batch culture the viability of clone 4.2 was the same with and without 
the pH being controlled. After that point, the viability of the cultures that lacked pH control 
dropped much more quickly than for the control cultures. After 12 days in batch culture 
clone 4.2, for which the pH was controlled, had a viability of 64%, while clone 4.2 
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Figure 6. Diagram of the pcDNA3. l/Hygro(-)/bcl-2 plasmid construct. This plasmid was 
made by cutting the bcl-2 fragment from pBcl2UHD and inserting into pcDNAS. l/Hygro(-) 
at the multiple cloning site. 
had a viability of 22% when the pH was not controlled. This suggests that the major reason 
for the decrease in the viable cell density and viability of clone 4.2 was the extreme change in 
pH. These results show that pH alone can not explain the increase in viability of the bcl-2 
expressing cell lines during the decline period of batch culture. Due to this study, the results 
for clone 4.2 after 8 day were ignored for determining the effect of BCL-2 in batch culture 
(Chapter 2). 
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Figure 7. RT-PCR of RNA samples from H166 clones that were stably transacted with 
pcDNA3.1/Hygro(-)/bcl-2. The bands indicate clones with increased bcl-2 RNA expression. 
The HL-60 cells are included as a positive control for bcl-2 expression. 
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Figure 8. Checking H166 cells transacted with pcDNAS. l/Hygro(-)/bcl-2 for BCL-2 content 
by Western blotting. The HL-60 cell lysates were included as positive controls for BCL-2 
content. The top band represents the BCL-2 protein, while the lower bands represent BCL-2 
fragments. The top band was quantitated in other blots to determine the BCL-2 content of 
each clone. 
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Figure 9. The effect of pH control on clone 4.2, which was modified for bcl-2 expression. 
A) The viable cell density of the vector-only control increased only slightly in cultures where 
the pH was maintained above 7. The viable cell density of clone 4.2, which expresses bcl-2, 
had a significant increase in viable cell density compared to the culture without pH control. 
B) Control of pH resulted in increased viability in clone 4.2. 
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Checking the mitochondria for BCL-2 localization 
After running the batch and perfusion experiments shown in chapters 2 and 3, the 
mitochondria of the bcl-2 modified cells were checked for BCL-2 content The amount of 
protection the cells gained from apoptosis was much less than that seen in previous studies 
(Itoh et al., 1995; Simpson et al., 1997). It has been suggested that BCL-2 localization to the 
mitochondria may be necessary for protection from apoptosis (Jia et al., 1999). For this 
reason, the cells were analyzed for BCL-2 localization. 
Figures 10 shows the results of a succinate-cytochrome c reductase assay which 
allowed for the isolation of the mitochondria fraction. These fractions were then analyzed by 
Western blotting and it was found that the mitochondria have a high BCL-2 content (Figure 
11). This suggests that the BCL-2 is active in the H166 hybridoma cells modified for bcl-2 
expression. 
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Figure 10. Determination of the mitochondrial fraction taken from a sucrose gradient 
generated by ultracentrifugation. The mitochondrial fraction exhibits an increase in 
absorbance after a succinate-cytochrome c reductase assay. 
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Figure 13. Western blotting of samples obtained by unltracentrifugation to check for bcl-2 
localization to the mitochondria. The mitochondrial fractions were obtained from a sucrose 
gradient, while an additional mitochondrial sample and a nuclear fragment were obtained by 
differential centrifugation. 
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APPENDIX C. ADDITIONAL DATA FROM BATCH STUDIES 
The material in this section is presented as supporting data for the experiments 
performed in chapter 2. 
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Figure 1. Variation in level of bcl-2 expressed by H166 bcl-2 clones during various runs as 
determined by quantitative Western blotting. One unit/cell of BCL-2 content is the amount 
of BCL-2 content in an HL-60 cell taken at 48 h of batch culture. 
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Figure 3. Mean glucose concentration of H166 clones that were modified to express human 
bcl-2. 
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Figure 4. Mean glutamine concentration of samples taken from batch cultures of cells 
modified to overexpress bcl-2. 
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Figure 5. Mean lactate concentration of samples taken from batch cultures of cells modified 
to overexpress bcl-2. 
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Figure 6. Mean ammonia concentration of samples taken from batch cultures of cells 
modified to overexpress bcl-2. 
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Figure 7. Mean specific antibody productivity of H166 clones modified for bcl-2 expression 
and that of a vector-only control. 
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Figure 8. Specific antibody productivities of various bcl-2 modified clones. (A) Clone 2.8, 
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Figure 9. Effect of BCL-2 overexpression on specific IgM production in batch culture. 
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Figure 10. Effect of bcl-2 expression on glucose consumption in batch culture. 
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Figure 11. Efifect of bcl-2 expression on glutamine consumption in batch culture. 
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Figure 12. Effect of bcl-2 expression on lactate production in batch culture. 
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Figure 13. Effect of bcl-2 expression on ammonia production in batch culture. 
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Figure 14. Flow cytometry analysis of BCL-2 vs. propidium iodide content. F FTC-
conjugated anti human BCL-2 antibody (DAKO) is used to fluorescently label cells with 
BCL-2 content. Propidium iodide is used as a counter stain for DNA content. Samples 
shown were taken from day 2 of batch culture from run #3. Clones 2.8 and 4.2 have an 
elevated level of fluorescence due to FITC, which indicates elevated BCL-2 content 
(A) Vector-only control (B) Clone 1.1 (1.6 units BCL-2/cell) (C) Clone 2.8 (27 units 
BCL-2/cell) (D) Clone 4.2 (10 units BCL-2/cell). 
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Figure 15. Determination of the percentage of cells that had BCL-2 content above that of the 
vector-only control. The gate was chosen such that only 2% of the vector-only control cells 
were positive, and then the clones were examined using this gate. The same samples are 
shown as in Figure 14. (A) Vector-only control (B) Clone 1.1 (C) Clone 2.8 (D) Clone 
4.2. 
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Figure 16. Determination of the number of cells in Gl, G2/M, and S phase of the cell cycle. 
Cells were taken from day 2 of batch culture for run #3 and stained with propidium iodide. 
Cells were counted on a Coulter Epics Elite flow cytometer. Gates were chosen such that the 
middle of gate M3 (represents S phase) is twice the intensity of the mean of gate Ml (Gl 
phase). The M2 gate (G2/S phase) was the same size as gate Ml. Results showed that bcl-2 
had little effect on cell cycle for H166 hybridoma cells. (A) Vector-only control (B) Clone 
1.1 (C) Clone 2.8 (D) Clone 4.2. 
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Figure 17. During batch run #2, some of the cells in the clone 2.8 culture appear to have lost 
bcl-2 expression. This is evident in the two peaks formed on a BCL-2/FITC histogram. This 
sample was taken at day 2 of batch culture. As a result, only 48% of the cells were found to 
be positive for BCL-2 content. (A) Density plot of BCL-2 vs. propidium iodide (B) BCL-2 
histogram. 
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APPENDIX D. ADDITIONAL DATA FROM PERFUSION STUDIES 
This material in this section is presented as supporting data for the experiments 
performed in chapter 3. 
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Figure 1. Western blot of cell lysates from H166 cells modified for bcl-2 expression and a 
vector-only control taken from steady state perfusion culture at a dilution rate of 2.0 v/d and 
a cell bleed rate of 0.75 v/d. HL-60 cell lysates were included as a positive control for BCL-
2 production. Clone 1.1 has a BCL-2 content that is about the same as the HL-60 control 
culture, while clones 2.8 and 4.2 have a significantly higher BCL-2 content. 
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Figure 2. Glucose concentrations in perfusion culture at various cell bleed rates. (A) 0.75 
v/d (B) 0.25, 0.1 v/d. 
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Figure 3. Glutamine concentration of H166 hybridoma cells modified for bcl-2 expression 
and of vector-only controls in perfusion culture at cell bleed rates of (A) 0.75 v/d, (B) 0.25, 
0.1 v/d. 
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Figure 4. Lactate concentration of H166 hybridoma cells modified for bcl-2 expression and 
of vector-only controls in perfusion culture at cell bleed rates of (A) 0.75 v/d, (B) 0.25,0.1 
v/d. 
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Figure 5. Ammonia concentration of H166 hybridoma cells modified for bcl-2 expression 
and of vector-only controls in perfusion culture at cell bleed rates of (A) 0.75 v/d, (B) 0.25, 
0.1 v/d. 
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Figure 6. Specific IgM production of H166 hybridoma cells modified for bcl-2 expression 
and of vector-only controls in perfusion culture at cell bleed rates of (A) 0.75 v/d, (B) 0.25, 
0.1 v/d. 
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Figure 7. Specific glucose consumption of H166 hybridoma cells modified for bcl-2 
expression and of vector-only controls in perfusion culture at cell bleed rates of (A) 0.75 v/d, 
(B) 0.25,0.1 v/d. 
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Figure 8. Specific glutamine consumption of H166 hybridoma cells modified for bcl-2 
expression and of vector-only controls in perfusion culture at cell bleed rates of (A) 0.75 v/d, 
(B) 0.25, 0.1 v/d. 
173 
A) 
o 
i l  
ë 
1  
4.0E-05 
Vector-only(l) 
Vector-only(2) 
Vector-only(3) 
Clone 1.1 
Clone 2.8 
Clone 4.2 
3.0E-05 
2.0E-05 
1.0E-05 
0.0E+00 
uE-05 
600 
Time (h) 
B) 
A 2.0E-05 
! 
§ 
1  
eu 
I  
o (C 
& 
CZ3 
1.5E-05 
1.0E-05 
5.0E-06 
0.0E+00 
Vector-only 
Clone 1.1 
Clone 2.8 
Clone 4.2 
0 200 400 600 
Time (h) 
800 1000 
Figure 9. Specific lactate consumption of H166 hybridoma cells modified for bcl-2 
expression and of vector-only controls in perfusion culture at cell bleed rates of (A) 0.75 v/d, 
(B) 0.25,0.1 v/d. 
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Figure 10. Specific ammonia consumption of H166 hybridoma cells modified for bcl-2 
expression and of vector-only controls in perfusion culture at cell bleed rates of (A) 0.75 v/d, 
(B) 0.25,0.1 v/d. 
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Table 1. Steady state IgM, substrate and metabolite concentrations. 
Bleed Rate IgM Glucose Glutamine Lactate Ammonia 
(v/d) (mg/1) (mg/ml) (mg/1) (mg/1) (mg/1) 
Vector-only (1) 0.75 8.0 ± 2.5 25.3 ± 1.9 315 ±73 11.9 ±2.5 47.8 ±42 
Vector-only (2) 0.75 18.2 ±4.0 24.5 ±42 345 ± 15 19.8 ±2.6 57.6 ± 5.9 
Vector-only (3) 0.75 19.0 ±4.0 24.1 ±4.4 358 ± 10 16.0 ± 1.6 51.2 ±6.8 
Clone 1.1 0.75 18.9 ±2.4 25.0 ± 23 356 ± 87 16.6 ± 1.9 72.8 ± 16.6 
Clone 2.8 0.75 24.4 ±73 21.8 ±22 288 ±24 14.4 ± 12 45.4 ±2.6 
Clone 4.2 0.75 10.8 ±33 223 ± 2.0 369 ±84 13.7 ±4.1 272 ±5.7 
Vector-only 025 12.7 ±3.3 25.6 ± 1.0 357±107 11.9 ± 13 57.9 ± 12.2 
Clone l.l 025 43.8 ± 10.3 25.0 ± 0.5 461 ±18 14.3 ± 1.6 52.2 ±17.6 
Clone 2.8 0.25 118± 16 24.8 ± 1.7 419± 138 13.0 ±2.0 55.2 ±4.5 
Clone 4.2 0.25 35.4 ±8.1 17.4 ±0.8 251 ±29 23.1 ± 1.5 59.7 ± 7.9 
Vector-only 0.1 41.2 18.8 ± 1.4 581 173 ± 1.6 66.8 ±92 
Clone 1.1 0.1 60.3 ± 152 20.6 ± 2.0 484 ± 142 15.7 ± 1.6 60.4 ± 12.3 
Clone 2.8 0.1 122 ±2 20.9 ± 2.0 492 ± 82 13.0 ±2.4 58.3 ± 72 
Clone 4.2 0.1 572 ±3.1 14.6 ±2.1 316 ± 54 25.1 ± 1.8 68.8 ±8.9 
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Table 2. Steady state bcl-2 content, % BCL-2 expressers, and apoptotic cell percentage in 
perfusion culture. 
Ren Bleed Rate 
(/d) 
BCL-2 Content 
(units/cell) 
BCL-2 Containing 
Cells (•/•) 
Apoptotic Cells 
(%) 
Vector-only (1) 0.75 0 0.60 ±0.44 
Vector-only (2) 0.75 0 - 0.72 ±026 
Vector-only (3) 0.75 0 - 0.74 ±038 
Clone 1.1 0.75 029 ± 0.02 0.58 ±036 0.29 ±026 
Clone 2.8 0.75 6.6 ±2.0 82.2 ±43 0.40 ±027 Clone 4.2 0.75 5.9 ±2.3 73.8 ± 9.6 0.69 ±0.58 
Vector-only 0.25 0 0.57 ± 0.56 
Clone l.l 025 039 ±0.01 7.4 ±2.9 0.74 ±0.15 
Clone 2.8 025 4.7 ±23 77.3 ±9.0 0.68 ± 0.42 
Clone 4.2 025 3.6 ±0.6 76.6 ± 7.4 0.90 ±037 
Vector-only 0.1 0 1.34 + 0.82 
Clone 1.1 0.1 0.33 ±0.06 0.8 ±0.8 1.43 ±037 
Clone 2.8 0.1 4.0 ± 12 68.4 ±4.8 1.41 ±033 
Clone 4.2 0.1 3.6 ±0.6 812 ±2.8 1.25 ±0.45 
